

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

 **ZEPATIER[®]**

elbasvir/grazoprevir tablets

50 mg/100 mg

Antiviral Agent

Merck Canada Inc.
16750 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.merck.ca

Date of Preparation:
January 19, 2016

Date of Revision:
June 28, 2017

Submission Control No: **204225**

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	4
WARNINGS AND PRECAUTIONS.....	5
ADVERSE REACTIONS.....	9
DRUG INTERACTIONS	14
DOSAGE AND ADMINISTRATION	25
OVERDOSAGE	27
ACTION AND CLINICAL PHARMACOLOGY	28
STORAGE AND STABILITY.....	31
SPECIAL HANDLING INSTRUCTIONS	31
DOSAGE FORMS, COMPOSITION AND PACKAGING	32
PART II: SCIENTIFIC INFORMATION	33
PHARMACEUTICAL INFORMATION.....	33
CLINICAL TRIALS.....	35
MICROBIOLOGY	49
TOXICOLOGY	55
REFERENCES	55
PART III: PATIENT MEDICATION INFORMATION	57

 **ZEPATIER®**

50 mg of elbasvir and 100 mg of grazoprevir

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
oral	Tablet 50 mg elbasvir and 100 mg grazoprevir	Lactose monohydrate <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

ZEPATIER® (elbasvir/grazoprevir) is indicated for the treatment of chronic hepatitis C (CHC) genotypes 1, 3, or 4 infection in adults as follows:

Without ribavirin:

- in genotype (GT) 1 or 4 treatment-naïve (TN) and peginterferon alfa + ribavirin (PR) treatment-experienced (TE) relapsers (12 weeks)
- in GT1 protease inhibitor (PI)/PR-TE relapsers (12 weeks)
- in GT1b TN, non-cirrhotic patients (8 weeks)
- in GT1b PR- or PI/PR-TE on-treatment virologic failures (12 weeks)

With ribavirin:

- in GT1a PR- or PI/PR-TE on-treatment virologic failures (16 weeks)
- in GT4 PR-TE on-treatment virologic failures (16 weeks)

With sofosbuvir:

- in GT3 TN patients (12 weeks)

(see **DOSAGE AND ADMINISTRATION**)

Geriatrics (> 65 years of age):

There were a limited number of geriatrics patients (N=187) included in the clinical trials. There was no overall difference in safety or efficacy observed in these patients (see **WARNINGS AND PRECAUTIONS, Special Populations**).

Pediatrics (< 18 years of age):

Safety and efficacy of ZEPATIER[®] have not been established in pediatric patients less than 18 years of age.

CONTRAINDICATIONS

- Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the Dosage Forms, Composition and Packaging section of the product monograph.
- If ZEPATIER[®] is administered with ribavirin or sofosbuvir, the contraindications to ribavirin or sofosbuvir also apply to this combination regimen. Refer to the ribavirin or sofosbuvir product monograph for a list of contraindications for ribavirin or sofosbuvir.
- ZEPATIER[®] is contraindicated in patients with moderate or severe hepatic impairment (see **WARNINGS AND PRECAUTIONS, Hepatic, ADVERSE REACTIONS and ACTION AND CLINICAL PHARMACOLOGY**).
- ZEPATIER[®] is contraindicated with inhibitors of organic anion transporting polypeptide 1B (OATP1B) that are known or expected to significantly increase grazoprevir plasma concentrations, strong inducers of cytochrome P450 3A (CYP3A), or efavirenz.

Table 1 - Drugs that are Contraindicated with ZEPATIER®

Mechanism of Interaction	Clinical Comment	Drugs that are Contraindicated with ZEPATIER®*
Inhibition of OATP1B by co-administered drug (see WARNINGS AND PRECAUTIONS, Drug Interactions)	May increase the risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations followed by decreases in elbasvir and grazoprevir plasma concentrations during continued coadministration (due to strong CYP3A induction).	Antimycobacterials rifampin
	May increase the risk of ALT elevations with OATP1B inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations	HIV medications atazanavir darunavir lopinavir saquinavir tipranavir Immunosuppressants Cyclosporine
Strong induction of CYP3A by co-administered drugs (see WARNINGS AND PRECAUTIONS, Drug Interactions)	May lead to loss of virologic response to ZEPATIER® due to significant decreases in elbasvir and grazoprevir plasma concentrations	Anticonvulsants phenytoin, carbamazepine Herbal products St. John's wort (<i>Hypericum perforatum</i>) HIV medications efavirenz [†]
<p>* This table is not a comprehensive list of all drugs that strongly induce CYP3A. This table may not include all OATP1B inhibitors that significantly increase grazoprevir plasma concentrations. [†] Efavirenz is included as a strong CYP3A inducer in this table, since co-administration reduced grazoprevir exposure by ≥ 80% (see Table 10)</p>		

WARNINGS AND PRECAUTIONS

Potential for Hepatitis B Virus (HBV) Reactivation: Screen all patients for evidence of current or prior HBV infection before initiating ZEPATIER® treatment. Cases of HBV reactivation, including those resulting in fulminant hepatitis, hepatic failure, and death, have been reported during hepatitis C virus (HCV) treatment and/or post-treatment with regimens containing HCV direct-acting antivirals (DAAs) in patients co-infected with HBV (see **WARNINGS AND PRECAUTIONS, Potential for Hepatitis B Virus Reactivation**).

General

Since ZEPATIER[®] is a fixed dose combination product, an adjustment of its recommended dose is not possible.

Potential for Hepatitis B Virus Reactivation:

Cases of HBV reactivation, including those resulting in fulminant hepatitis, hepatic failure, and death have been reported in HCV/HBV co-infected patients who were undergoing, or completed treatment with DAAs. To decrease the risk of HBV reactivation in patients co-infected with HBV, HBV screening should be performed in all patients prior to initiation of HCV treatment. Patients with positive HBV serology (HBsAg positive) and patients with serologic evidence of resolved HBV infection (i.e. HBsAg negative and anti-HBc positive) should be monitored and treated according to current clinical practice guidelines to manage potential for HBV reactivation (see **WARNINGS AND PRECAUTIONS, Monitoring and Laboratory Tests**).

Risks Associated with Ribavirin Combination

If ZEPATIER[®] is administered with ribavirin, the warnings and precautions for ribavirin, including the pregnancy avoidance warning, also apply to this combination regimen. Refer to the ribavirin product monograph for a list of warnings and precautions for ribavirin.

Risks Associated with Sofosbuvir Combination

If ZEPATIER[®] is administered with sofosbuvir, the warnings and precautions for sofosbuvir, also apply to this combination regimen. Refer to the sofosbuvir prescribing information for a list of warnings and precautions for sofosbuvir.

Drug Interactions

Co-administration of ZEPATIER[®] and OATP1B inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations is contraindicated (see **CONTRAINDICATIONS and DRUG INTERACTIONS, Effects of Other Drugs on ZEPATIER[®]**).

The concomitant use of ZEPATIER[®] and strong CYP3A inducers or efavirenz may significantly decrease elbasvir and grazoprevir plasma concentrations and may lead to a reduced therapeutic effect of ZEPATIER[®]. Therefore, the use of ZEPATIER[®] with strong CYP3A inducers or efavirenz is contraindicated (see **CONTRAINDICATIONS and DRUG INTERACTIONS, Effects of Other Drugs on ZEPATIER[®]**).

The concomitant use of ZEPATIER[®] and moderate CYP3A inducers may decrease elbasvir and grazoprevir plasma concentrations and may lead to a reduced therapeutic effect of ZEPATIER[®]. Therefore, the use of ZEPATIER[®] with moderate CYP3A inducers is not recommended. (see **DRUG INTERACTIONS, Effects of Other Drugs on ZEPATIER[®] and Table 8**).

The concomitant use of ZEPATIER[®] and strong CYP3A inhibitors increases elbasvir and grazoprevir concentrations. Co-administration of ZEPATIER with certain strong CYP3A inhibitors is not recommended. (see **DRUG INTERACTIONS, Effects of Other Drugs on ZEPATIER[®] and Table 8**).

The plasma concentration of grazoprevir is increased if ZEPATIER[®] is co-administered with cyclosporine. Co-administration with cyclosporine is contraindicated (see **CONTRAINDICATIONS**).

See Table 8 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during ZEPATIER[®] therapy; review concomitant medications during ZEPATIER[®] therapy; and monitor for the adverse reactions associated with the concomitant drugs (see **CONTRAINDICATIONS and DRUG INTERACTIONS**).

Hepatic

Increased Risk of ALT Elevations

During clinical trials with ZEPATIER[®] with or without ribavirin, < 1% of subjects experienced elevations of ALT from normal levels to greater than 5 times the upper limit of normal (ULN), generally at or after treatment week 8. ALT elevations were typically asymptomatic and most resolved with ongoing or completion of therapy. Higher rates of late ALT elevations occurred in females (2% [11/652]), Asians (2% [4/165]), and subjects aged ≥ 65 years (2% [3/187]). (see **ADVERSE REACTIONS**).

Hepatic laboratory testing should be performed prior to therapy, at treatment week 8, and as clinically indicated. For patients receiving 16 weeks of therapy, additional hepatic laboratory testing should be performed at treatment week 12.

- Patients should be instructed to consult their healthcare professional without delay if they have onset of fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discolored feces.
- ZEPATIER[®] should be discontinued if ALT levels remain persistently greater than 10 times the ULN or accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or International Normalized Ratio (INR).

Hepatic Impairment

ZEPATIER[®] may be used as recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER[®] is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B and Child-Pugh C, respectively) due to a lack of clinical safety and efficacy experience in these patient populations, the expected increase in grazoprevir exposure (approximately 5- or 12-fold, respectively), and the increased risk of late ALT elevations. (see **CONTRAINDICATIONS and ACTION AND CLINICAL PHARMACOLOGY**).

Liver Transplant Patients

The safety and efficacy of ZEPATIER[®] have not been established in patients awaiting liver transplant or in liver transplant recipients.

Special Populations

Pregnant Women

Pregnancy should be avoided while taking ZEPATIER[®] as there are no data on the use of ZEPATIER[®] in pregnant women. Patients should be advised to notify their health care provider immediately in the event of a pregnancy. ZEPATIER[®] should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus.

Elbasvir: No effects on embryo-fetal development or maternal toxicity have been observed in rats or rabbits when dams were administered elbasvir up to the highest dose tested (approximately 9 and 17 times the clinical dose based on AUC, respectively). In both species, elbasvir was shown to cross the placenta. In the pre- and postnatal study, no effects have been observed in rat offspring when exposed in utero (via maternal dosing) and during lactation (via maternal milk) up to the highest maternal exposure tested (approximately 9 times the clinical dose based on AUC).

Grazoprevir: No effects on embryo-fetal development or maternal toxicity have been observed in rats or rabbits when dams were administered grazoprevir up to the highest dose tested (approximately 110 and 39 times the clinical dose based on AUC, respectively). In both species, grazoprevir was shown to cross the placenta. In the pre- and postnatal study, no effects have been observed in rat offspring when exposed in utero (via maternal dosing) and during lactation (via maternal milk) up to the highest maternal exposure tested (approximately 79 times the clinical dose based on AUC).

Nursing Women

There are no human data to assess whether ZEPATIER[®] is excreted in human breast milk. A risk to the newborn/infant cannot be excluded, therefore mothers should be instructed not to breastfeed if they are taking ZEPATIER[®]. Elbasvir and grazoprevir are excreted in the milk of lactating rats. Concentrations of elbasvir were higher and concentrations of grazoprevir were lower in breast milk than maternal plasma in rats.

Females and Males of Reproductive Potential

No human data on the effect of elbasvir and grazoprevir on fertility are available. In rats, elbasvir and grazoprevir had no effect on fertility when tested at approximately 9 and 117 times the clinical dose based on AUC, respectively.

Pediatrics (< 18 years of age)

Safety and efficacy of ZEPATIER[®] have not been established in pediatric patients less than 18 years of age.

Geriatrics (> 65 years of age)

Clinical trials of ZEPATIER[®] with or without ribavirin included 187 subjects aged 65 and over. Although higher elbasvir and grazoprevir plasma concentrations were observed in subjects aged 65 and over, no overall differences in safety or efficacy were observed between subjects aged 65 and over and younger (see **ACTION AND CLINICAL PHARMACOLOGY**).

Renal Impairment

In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²) or with end stage renal disease (ESRD), including patients on hemodialysis, it is recommended to administer ZEPATIER[®] without ribavirin (see **DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY**).

Other HCV Genotypes

Safety and efficacy of ZEPATIER[®] have not been established in patients infected with HCV genotypes 2, 5, and 6. (see **INDICATIONS AND CLINICAL USE**)

HCV/HIV-1 co-infection

Co-administration of ZEPATIER[®] and OATP1B inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations (including HIV protease inhibitors), is contraindicated. The use of ZEPATIER[®] with strong CYP3A inducers or efavirenz is contraindicated. The use of ZEPATIER[®] with moderate CYP3A inducers and the fixed-dose combination of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate is not recommended (see **DRUG INTERACTIONS**).

HCV/HBV Co-Infection

The safety and efficacy of ZEPATIER[®] have not been studied in HCV patients co-infected with HBV. HBV reactivation has been reported during treatment and post-treatment with DAAs in patients co-infected with HBV who were not undergoing treatment for HBV infection (see **WARNINGS AND PRECAUTIONS, Potential for Hepatitis B Virus Reactivation**).

Monitoring and Laboratory Tests

Clearance of HCV may lead to increased replication of HBV in patients who are co-infected with HCV and HBV; co-infected patients should be monitored for clinical and laboratory signs (e.g. HBsAg, anti-HBc, HBV DNA, serum aminotransferase levels, bilirubin) for HBV reactivation or hepatitis flare-during and at post-treatment follow-up as clinically appropriate (see **WARNINGS AND PRECAUTIONS, Potential for Hepatitis B Virus Reactivation**).

ADVERSE REACTIONS

Adverse Drug Reaction Overview

If ZEPATIER[®] is administered with ribavirin or sofosbuvir, refer to the product monographs for ribavirin or sofosbuvir for a list of ribavirin or sofosbuvir-associated adverse reactions.

The safety summary of ZEPATIER[®] was based on data from two placebo-controlled trials and eight uncontrolled Phase 2 and 3 clinical trials in approximately 2,000 subjects with chronic hepatitis C infection with compensated liver disease (with or without cirrhosis) who received ZEPATIER[®] with or without ribavirin (see **CLINICAL TRIALS**).

Adverse Reactions in Subjects Receiving ZEPATIER[®] Alone

C-EDGE TN was a Phase 3 placebo-controlled trial in treatment-naïve (TN) subjects. The most commonly reported adverse reactions (adverse events assessed as causally related by the investigator, all grades) occurring in C-EDGE TN at $\geq 10\%$ frequency in subjects treated with ZEPATIER[®] for 12 weeks were fatigue and headache. No subjects had serious adverse reactions. The proportion of subjects who permanently discontinued treatment due to adverse reactions was $< 1\%$.

In a pooled analysis of Phase 2 and 3 clinical trials in subjects treated with ZEPATIER[®] for 12 weeks, the most commonly reported adverse reactions (greater than 10% of subjects) were fatigue and headache. The majority of the adverse reactions were mild in severity. No subjects treated with ZEPATIER[®] had serious adverse reactions. The proportion of subjects who permanently discontinued treatment due to adverse reactions was $< 1\%$. The type and severity of adverse reactions in subjects with cirrhosis were comparable to those seen in subjects without cirrhosis.

Adverse Reactions in Subjects Receiving ZEPATIER[®] with Ribavirin

C-EDGE TE was a Phase 3 open-label trial in treatment-experienced (TE) subjects. The most commonly reported adverse reactions occurring in C-EDGE TE at $\geq 10\%$ frequency in subjects treated with ZEPATIER[®] with ribavirin for 16 weeks were fatigue, headache, anemia and nausea. The majority of the adverse reactions were mild in severity. The proportion of subjects treated with ZEPATIER[®] with ribavirin with serious adverse reactions was $< 1\%$. The portion of subjects who permanently discontinued treatment due to adverse reactions was 2%. The type and severity of adverse reactions in subjects with cirrhosis were comparable to those seen in subjects without cirrhosis.

ZEPATIER[®] in Subjects with Advanced Chronic Kidney Disease

The safety of elbasvir and grazoprevir in comparison to placebo in subjects with advanced chronic kidney disease (severe renal impairment or ESRD, including patients on hemodialysis) and genotype 1 CHC infection with compensated liver disease (with or without cirrhosis) was assessed in 235 subjects (C-SURFER) (see **CLINICAL TRIALS**). The most commonly reported adverse reactions occurring at $\geq 10\%$ frequency in subjects treated with ZEPATIER[®] were nausea and headache. The majority of the adverse reactions were mild in severity. No subjects experienced a serious adverse reaction or discontinued treatment due to adverse reactions.

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Adverse Reactions in Subjects Receiving ZEPATIER® Alone

Adverse reactions (adverse events assessed as causally related by the investigator, all grades) occurring at $\geq 5\%$ frequency in subjects treated with ZEPATIER® for 12 weeks in C-EDGE TN or with ZEPATIER® for 12 weeks in the pooled analysis of Phase 2 and 3 clinical trials are presented in Table 2.

Table 2 - Adverse Reactions Occurring at $\geq 5\%$ Frequency in Subjects with Chronic Hepatitis C Infection Treated with ZEPATIER® for 12 Weeks in C-EDGE TN or with ZEPATIER® for 12 weeks in the Pooled Phase 2 and 3 Clinical Trials

	C-EDGE TN		Pooled [†]
	ZEPATIER® N=316 % (n) 12 weeks	Placebo N=105 % (n) 12 weeks	ZEPATIER® N=834 % (n) 12 weeks
Fatigue	11% (35)	10% (10)	11% (94)
Headache	10% (31)	9% (9)	10% (86)
Nausea	4% (14)	5% (5)	5% (43)

[†]Includes C-WORTHY, C-SCAPE, C-SALT, C-EDGE TN, C-EDGE COINFECTION, C-EDGE TE and P058

The type and severity of adverse reactions were comparable among subjects treated with 8, 12 or 16 weeks of ZEPATIER®.

Common Clinical Trial Adverse Drug Reactions ($\geq 1\%$ to $< 5\%$)

Adverse reactions occurring in a pooled analysis of Phase 2 and 3 clinical trials at $\geq 1\%$ to $< 5\%$ frequency in subjects treated with ZEPATIER® for 12 weeks are listed below by body system (Table 3).

Table 3 - Adverse Reactions Occurring at $\geq 1\%$ to $< 5\%$ Frequency in Subjects with Chronic Hepatitis C Infection Treated with ZEPATIER® for 12 weeks in the Pooled Phase 2 and 3 Clinical Trials

Body System	Adverse Drug Reactions (%)
Gastrointestinal disorders:	Abdominal pain (2%), abdominal pain upper (2%), constipation (2%), diarrhea (3%), dry mouth (1%), vomiting (1%)
General disorders and administration site conditions:	Asthenia (4%)
Metabolism and nutrition disorders:	Decreased appetite (2%)
Musculoskeletal and connective tissue disorders:	Arthralgia (2%), myalgia (2%)
Nervous system disorders:	Dizziness (2%)
Psychiatric disorders:	Anxiety (1%), depression (1%), insomnia (3%), irritability (2%)
Skin and subcutaneous tissue disorders:	Alopecia (1%), pruritus (1%)

Adverse Reactions in Subjects Receiving ZEPATIER® with Ribavirin

Adverse reactions occurring in C-EDGE TE at $\geq 5\%$ frequency in subjects treated with ZEPATIER® with ribavirin for 16 weeks are presented in Table 4.

Table 4 - Adverse Reactions Occurring at $\geq 5\%$ Frequency in Subjects with Chronic Hepatitis C Infection Treated with ZEPATIER[®] + Ribavirin for 16 Weeks in C-EDGE TE

	C-EDGE TE
	ZEPATIER[®] + Ribavirin
	N=106
	% (n)
	16 weeks
Fatigue	25% (27)
Headache	17% (18)
Anemia	16% (17)
Nausea	12% (13)
Pruritus	9% (10)
Asthenia	8% (9)
Dyspepsia	6% (6)
Dyspnea	8% (9)
Hemoglobin decreased	7% (7)
Dyspnea exertional	6% (6)
Insomnia	6% (6)
Myalgia	6% (6)
Vomiting	6% (6)
Decreased appetite	5% (5)
Cough	5% (5)
Irritability	5% (5)
Rash	5% (5)

Common Clinical Trial Adverse Drug Reactions ($\geq 1\%$ to $< 5\%$)

Adverse reactions occurring in C-EDGE TE at $\geq 1\%$ to $< 5\%$ frequency in subjects treated with ZEPATIER[®] with ribavirin for 16 weeks are listed below by body system (Table 5).

Table 5 - Adverse Reactions Occurring at $\geq 1\%$ to $< 5\%$ Frequency in Subjects with Chronic Hepatitis C Infection Treated with ZEPATIER[®] + Ribavirin for 16 Weeks in C-EDGE TE

Body System	Adverse Drug Reactions (%)
Blood and lymphatic system disorders:	Haemolytic anemia (2%)
Cardiac disorders:	Palpitations (2%)
Eye disorders:	Ocular icterus (2%)
Gastrointestinal disorders:	Abdominal pain (2%), constipation (3%), diarrhea (4%), flatulence (2%)
Hepatobiliary disorders:	Hyperbilirubinaemia (2%)
Investigations:	Haematocrit decreased (2%)
Musculoskeletal and connective tissue disorders:	Arthralgia (2%)
Nervous system disorders:	Dizziness (3%), dysgeusia (3%), lethargy (2%), memory impairment (2%), presyncope (2%)
Psychiatric disorders:	Anxiety (2%), depression (3%), sleep disorder (3%)
Skin and subcutaneous tissue disorders:	Alopecia (3%), dry skin (4%), pruritus generalized (2%), rash maculo-papular (2%)

Abnormal Hematologic and Clinical Chemistry Findings in Subjects Receiving

ZEPATIER[®] with or without Ribavirin

Serum Late ALT Elevations

During clinical trials with ZEPATIER[®] with or without ribavirin, regardless of treatment duration, < 1% (13/1690) of subjects experienced elevations of ALT from normal levels to greater than 5 times the ULN, generally at or after treatment week 8 (mean onset time 10 weeks, range 6-12 weeks). Most late ALT elevations resolved with ongoing therapy with ZEPATIER[®] or after completion of therapy. The frequency of late ALT elevations was higher in subjects with higher grazoprevir plasma concentration. The incidence of late ALT elevations was not affected by treatment duration. Cirrhosis was not a risk factor for late ALT elevations. (see **WARNINGS AND PRECAUTIONS, Hepatic, DRUG INTERACTIONS and ACTION AND CLINICAL PHARMACOLOGY**)

Serum Bilirubin Elevations

During clinical trials with ZEPATIER[®] with or without ribavirin, regardless of treatment duration, elevations in bilirubin at greater than 2.5 times ULN were observed in 6% of subjects receiving ZEPATIER[®] with ribavirin compared to < 1% in those receiving ZEPATIER[®] alone. These bilirubin increases were predominantly indirect bilirubin and were generally observed in association with ribavirin co-administration. Bilirubin elevations were typically not associated with serum ALT elevations.

Decreased Hemoglobin

During clinical trials with ZEPATIER[®] with or without ribavirin, the mean change from baseline in hemoglobin levels in subjects treated with ZEPATIER[®] for 12 weeks was -0.19 mmol/L (-0.3g/dL) and with ZEPATIER[®] with ribavirin for 16 weeks was approximately -1.37 mmol/L (-2.2 g/dL). Hemoglobin declined during the first 8 weeks of treatment, remained low during the remainder of treatment, and normalized to baseline levels during follow-up. Less than 1% of subjects treated with ZEPATIER[®] with ribavirin had hemoglobin levels decrease to less than 5.28 mmol/L (8.5 g/dL) during treatment. No subjects treated with ZEPATIER[®] alone had a hemoglobin level less than 5.28 mmol/L (8.5 g/dL).

ZEPATIER[®] in Subjects with HCV/HIV-1 Co-Infection

The type and severity of adverse reactions in subjects with HCV/HIV-1 co-infection (n=298) were comparable to subjects without HCV/HIV-1 co-infection.

ZEPATIER[®] in Subjects with Advanced Chronic Kidney Disease

The adverse reactions occurring in C-SURFER at $\geq 5\%$ frequency in subjects treated with ZEPATIER[®] for 12 weeks are presented in Table 6.

Table 6 - Adverse Reactions Occurring at $\geq 5\%$ Frequency in Subjects with Advanced Chronic Kidney Disease and Chronic Hepatitis C Infection Treated with ZEPATIER[®] in C-SURFER

	ZEPATIER[®] N=122 % (n) 12 weeks	Placebo N=113 % (n) 12 weeks
Nausea	11% (14)	8% (9)
Headache	11% (14)	5% (6)
Fatigue	5% (6)	8% (9)

Common Clinical Trial Adverse Drug Reactions ($\geq 1\%$ to $< 5\%$)

Adverse reactions occurring in C-SURFER at $\geq 1\%$ to $< 5\%$ frequency in subjects during treatment with ZEPATIER[®] for 12 weeks are listed below by body system (Table 7).

Table 7 - Adverse Reactions Occurring at $\geq 1\%$ to $< 5\%$ Frequency in Subjects with Advanced Chronic Kidney Disease and Chronic Hepatitis C Infection Treated with ZEPATIER[®] in C-SURFER

Body System	Adverse Drug Reactions (%)
Ear and labyrinth disorders	Tinnitus (2%)
Gastrointestinal disorders:	Diarrhoea (2%), dry mouth (2%), dyspepsia (2%), flatulence (2%), vomiting (2%)
General disorders and administration site conditions:	Asthenia (4%)
Investigations:	Blood creatine phosphokinase increased (2%)
Metabolism and nutrition disorders:	Decreased appetite (2%)
Nervous system disorders:	Dizziness (3%)
Psychiatric disorders:	Insomnia (4%)
Skin and subcutaneous tissue disorders	Night sweats (2%), pruritus (2%)

Adverse Reactions in Subjects Receiving ZEPATIER[®] with Sofosbuvir

The safety of ZEPATIER[®] with sofosbuvir in treatment-naïve subjects with chronic hepatitis C genotype 3 infection was assessed in 143 subjects (C-SWIFT safety population). No adverse reactions were reported at $\geq 5\%$ frequency. The adverse reactions occurring at $\geq 1\%$ to $< 5\%$ frequency were diarrhea (1%), fatigue (1%), nausea (2%) and headache (3%). No subjects treated with ZEPATIER[®] had serious adverse reactions and no subjects permanently discontinued treatment due to adverse reactions) (see **CLINICAL TRIALS**).

DRUG INTERACTIONS

Overview

(See also **CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Drug Interactions**)

As ZEPATIER[®] contains elbasvir and grazoprevir, interactions that have been identified with these agents individually may occur with ZEPATIER[®].

Effects of Other Drugs on ZEPATIER[®]

Grazoprevir is a substrate of OATP1B drug transporters. Co-administration of ZEPATIER[®] with OATP1B inhibitors that are known or expected to significantly increase grazoprevir plasma concentrations is contraindicated (see **CONTRAINDICATIONS**).

Elbasvir and grazoprevir are substrates of CYP3A and P-gp. Co-administration of strong inducers of CYP3A or efavirenz with ZEPATIER[®] may significantly decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER[®]. Co-administration of ZEPATIER[®] with strong CYP3A inducers or efavirenz is contraindicated (see **CONTRAINDICATIONS**).

Co-administration of moderate inducers of CYP3A with ZEPATIER[®] may decrease elbasvir and grazoprevir plasma concentrations, leading to reduced therapeutic effect of ZEPATIER[®]. Co-administration of ZEPATIER[®] with moderate CYP3A inducers is not recommended (see **WARNINGS AND PRECAUTIONS, Drug Interactions and Table 8**).

Co-administration of ZEPATIER[®] with strong CYP3A inhibitors increases elbasvir and grazoprevir plasma concentrations. Co-administration of ZEPATIER[®] with certain strong CYP3A inhibitors is not recommended (see **WARNINGS AND PRECAUTIONS, Drug Interactions and Table 8**). Co-administration of ZEPATIER[®] with P-gp inhibitors is expected to have a minimal effect on the plasma concentrations of ZEPATIER[®].

Effects of ZEPATIER[®] on Other Drugs

Elbasvir and grazoprevir are inhibitors of the drug transporter breast cancer resistance protein (BCRP) at the intestinal level in humans and may increase plasma concentrations of co-administered BCRP substrates. Elbasvir is not a CYP3A inhibitor *in vitro* and grazoprevir is a weak, but not clinically relevant, CYP3A inhibitor in humans. Therefore, no dose adjustment is required for CYP3A substrates when co-administered with ZEPATIER[®].

Elbasvir has minimal intestinal P-gp inhibition in humans and grazoprevir is not a P-gp inhibitor *in vitro*. Therefore, P-gp substrates may be administered without dose adjustment when co-administered with ZEPATIER[®]. Elbasvir and grazoprevir are not OATP1B inhibitors in humans. Clinically significant drug interactions with ZEPATIER[®] as an inhibitor of other CYP enzymes, UGT1A1, esterases (CES1, CES2, and CatA), organic anion transporters (OAT)1 and OAT3, and organic cation transporter (OCT)2 are not expected. *In vitro*, elbasvir and grazoprevir did not induce CYP1A2, CYP2B6, or CYP3A.

As liver function may change during treatment with ZEPATIER[®], a close monitoring of INR values is recommended in patients treated with vitamin K antagonists.

Drug-Drug Interactions

Established and other Potential Drug Interactions

If dose adjustments of concomitant medications are made due to treatment with ZEPATIER[®], doses should be readjusted after administration of ZEPATIER[®] is completed.

Table 8 provides a listing of established or potentially clinically significant drug interactions. The drug interactions described are based on studies conducted with either ZEPATIER[®], the components of ZEPATIER[®] (elbasvir [EBR] and grazoprevir [GZR]) as individual agents, or are predicted drug interactions that may occur with ZEPATIER[®] (see **WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS, Drug Interactions Studies**).

Table 8 - Potentially Significant Drug Interactions: Alteration in Dose May Be Recommended Based on Results from Drug Interaction Studies or Predicted Interactions^b

Concomitant Drug Class: Drug Name	Effect on Concentration[†]	Clinical Comment
Antifungals ketoconazole [‡]	↑ EBR ↑ GZR	Concomitant use of systemic ketoconazole and ZEPATIER [®] increases grazoprevir exposure and may increase the overall risk of hepatotoxicity; co-administration of ketoconazole is not recommended.
Endothelin Antagonist: bosentan	↓ EBR ↓ GZR	Co-administration of ZEPATIER [®] with bosentan, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER [®] . Co-administration is not recommended.
Immunosuppressants: tacrolimus [‡]	↑ tacrolimus	Co-administration of ZEPATIER [®] with systemic tacrolimus increases the concentrations of tacrolimus. Frequent monitoring of tacrolimus whole blood concentrations, changes in renal function, and tacrolimus-associated adverse events upon the initiation of co-administration is recommended.
HIV Medications:		
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate [‡] or alafenamide (fixed-dose combination)	↑ EBR ↑ GZR	Co-administration of ZEPATIER [®] with the fixed-dose combination of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate or alafenamide resulted in or may result in increases in EBR and GZR concentrations. Co-administration is not recommended.
etravirine	↓ EBR ↓ GZR	Co-administration of ZEPATIER [®] with etravirine, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER [®] . Co-administration is not recommended.
HMG-CoA Reductase Inhibitors[#]:		
atorvastatin [‡]	↑ atorvastatin	Co-administration of EBR and GZR with atorvastatin increases the concentrations of atorvastatin. The dose of atorvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER [®] . [#]
rosuvastatin [‡]	↑ rosuvastatin	Co-administration of EBR and GZR and with rosuvastatin increases the concentrations of rosuvastatin. The dose of rosuvastatin should not exceed a daily dose of 10 mg when co-administered with ZEPATIER [®] . [#]
fluvastatin lovastatin simvastatin	↑ fluvastatin ↑ lovastatin ↑ simvastatin	Co-administration of ZEPATIER [®] with these statins has not been studied but may increase the concentrations of these statins. The dose of fluvastatin, lovastatin, or simvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER [®] . [#]
Kinase Inhibitor Sunitinib	↑ sunitinib	Co-administration of ZEPATIER [®] with sunitinib may increase sunitinib concentrations leading to an increased risk of sunitinib-associated adverse events. Use with caution.
Wakefulness-Promoting Agents: modafinil	↓ EBR ↓ GZR	Co-administration of ZEPATIER [®] with modafinil, a moderate CYP3A inducer, may decrease EBR and GZR concentrations, leading to reduced therapeutic effect of ZEPATIER [®] . Co-administration is not recommended.

^bThis table is not all inclusive.

†↓ = decrease, †↑ = increase.

‡ These interactions have been studied in healthy adults.

#See **DRUG INTERACTIONS**, section below: Drugs without Clinically Significant Interactions with ZEPATIER[®] for a list of HMG Co-A reductase inhibitors without clinically relevant interactions with ZEPATIER[®].

Drugs without Clinically Significant Interactions with ZEPATIER[®]

The interaction between the components of ZEPATIER[®] (elbasvir or grazoprevir) or ZEPATIER[®] and the following drugs were evaluated in clinical studies, and no dose adjustments are needed when ZEPATIER[®] is used with the following drugs individually: acid reducing agents (proton pump inhibitors, H2 blockers, antacids), buprenorphine/naloxone, digoxin, dolutegravir, methadone, mycophenolate mofetil, oral contraceptive pills, phosphate binders, pravastatin, prednisone, raltegravir, ribavirin, rilpivirine, tenofovir disoproxil fumarate, and sofosbuvir (see **DRUG INTERACTIONS, Drug Interactions Studies**).

No clinically relevant drug-drug interaction is expected when ZEPATIER[®] is co-administered with abacavir, emtricitabine, entecavir, and lamivudine.

Drug Interaction Studies

Drug interaction studies were performed in healthy adults with elbasvir, grazoprevir, or co-administered elbasvir and grazoprevir and drugs likely to be co-administered or drugs commonly used as probes for pharmacokinetic interactions. Table 9 summarizes the effects of co-administered drugs on the exposures of the individual components of ZEPATIER[®] (elbasvir and grazoprevir). Table 10 summarizes the effects of the individual components of ZEPATIER[®] on the exposures of the co-administered drugs. For information regarding clinical recommendations, see **WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS, Drug-Drug Interactions**.

Grazoprevir is a substrate of OATP1B. Co-administration of ZEPATIER[®] with drugs that inhibit OATP1B transporters may result in a clinically relevant increase in grazoprevir plasma concentrations.

Clinically significant drug interactions with ZEPATIER[®] as an inhibitor of other CYP enzymes, UGT1A1, esterases (CES1, CES2, and CatA), organic anion transporters (OAT)1 and OAT3, and organic cation transporter (OCT)2 are not expected. *In vitro*, elbasvir and grazoprevir did not induce CYP1A2, CYP2B6, or CYP3A. A clinical interaction study with montelukast confirmed that grazoprevir is not a CYP2C8 inhibitor (CYP isoform with lowest *in vitro* IC₅₀).

Elbasvir has minimal intestinal P-gp inhibition in humans, and does not result in clinically relevant increases in concentrations of digoxin (a P-gp substrate), with an 11% increase in plasma AUC (see Table 10). Grazoprevir is not a P-gp inhibitor *in vitro*. Therefore, P-gp substrates may be administered without dose adjustment when co-administered with ZEPATIER[®].

Elbasvir and grazoprevir are inhibitors of the drug transporter breast cancer resistance protein (BCRP) at the intestinal level in humans and may increase plasma concentrations of

co-administered BCRP substrates. Neither elbasvir nor grazoprevir are inhibitors of OATP1B in humans.

Table 9 - Drug Interactions: Changes in Pharmacokinetics of Elbasvir or Grazoprevir in the Presence of Co-Administered Drug

Co-Administered Drug	Regimen of Co-Administered Drug	Regimen of EBR or/and GZR	N	Geometric Mean Ratio [90% CI] of EBR and GZR PK with/without Co-Administered Drug (No Effect=1.00)			
					AUC [§]	C _{max}	C ₂₄
Antifungal							
Ketoconazole	400 mg once daily	EBR 50 mg single-dose	7	EBR	1.80 (1.41, 2.29)	1.29 (1.00, 1.66)	1.89 (1.37, 2.60)
	400 mg once daily	GZR 100 mg single-dose	8	GZR	3.02 (2.42, 3.76)	1.13 (0.77, 1.67)	--
Antimycobacterial							
Rifampin	600 mg single-dose IV	EBR 50 mg single-dose	14	EBR	1.22 (1.06, 1.40)	1.41 (1.18, 1.68)	1.31 (1.12, 1.53)
	600 mg single-dose PO	EBR 50 mg single-dose	14	EBR	1.17 (0.98, 1.39)	1.29 (1.06, 1.58)	1.21 (1.03, 1.43)
	600 mg PO once daily	GZR 200 mg once daily	12	GZR	0.93 (0.75, 1.17)	1.16 (0.82, 1.65)	0.10 (0.07, 0.13)
	600 mg IV single-dose	GZR 200 mg single-dose	12	GZR	10.21 (8.68, 12.00)	10.94 (8.92, 13.43)	1.77 (1.40, 2.24)
	600 mg PO single-dose	GZR 200 mg once daily	12	GZR	8.35 (7.38, 9.45) [†]	6.52 (5.16, 8.24)	1.62 (1.32, 1.98)
HCV Antiviral							
EBR	20 mg once daily	GZR 200 mg once daily	10	GZR	0.90 (0.63, 1.28)	0.87 (0.50, 1.52)	0.94 (0.77, 1.15)
GZR	200 mg once daily	EBR 20 mg once daily	10	EBR	1.01 (0.83, 1.24)	0.93 (0.76, 1.13)	1.02 (0.83, 1.24)
HIV Protease Inhibitor							
Atazanavir/ ritonavir	300 mg/ 100 mg once daily	EBR 50 mg once daily	10	EBR	4.76 (4.07, 5.56)	4.15 (3.46, 4.97)	6.45 (5.51, 7.54)
	300 mg/ 100 mg once daily	GZR 200 mg once daily	12	GZR	10.58 (7.78, 14.39)	6.24 (4.42, 8.81)	11.64 (7.96, 17.02)
Darunavir/ ritonavir	600 mg/ 100 mg twice daily	EBR 50 mg once daily	10	EBR	1.66 (1.35, 2.05)	1.67 (1.36, 2.05)	1.82 (1.39, 2.39)
	600 mg/ 100 mg twice daily	GZR 200 mg once daily	13	GZR	7.50 (5.92, 9.51)	5.27 (4.04, 6.86)	8.05 (6.33, 10.24)
Lopinavir/ ritonavir	400 mg/ 100 mg	EBR 50 mg once daily	10	EBR	3.71 (3.05, 4.53)	2.87 (2.29, 3.58)	4.58 (3.72, 5.64)

	twice daily						
	400 mg/ 100 mg twice daily	GZR 200 mg once daily	13	GZR	12.86 (10.25, 16.13)	7.31 (5.65, 9.45)	21.70 (12.99, 36.25)
Ritonavir [†]	100 mg twice daily	GZR 200 mg single-dose	10	GZR	2.03 (1.60, 2.56)	1.15 (0.60, 2.18)	1.88 (1.65, 2.14)
HIV Integrase Strand Transfer Inhibitor							
Dolutegravir	50 mg single-dose	EBR 50 mg + GZR 200 mg once daily	12	EBR	0.98 (0.93, 1.04)	0.97 (0.89, 1.05)	0.98 (0.93, 1.03)
	50 mg single-dose	EBR 50 mg once + GZR 200 mg once daily	12	GZR	0.81 (0.67, 0.97)	0.64 (0.44, 0.93)	0.86 (0.79, 0.93)
Raltegravir	400 mg single-dose	EBR 50 mg single-dose	10	EBR	0.81 (0.57, 1.17)	0.89 (0.61, 1.29)	0.80 (0.55, 1.16)
	400 mg twice daily	GZR 200 mg once daily	11	GZR	0.89 (0.72, 1.09)	0.85 (0.62, 1.16)	0.90 (0.82, 0.99)
HIV Non-Nucleoside Reverse Transcriptase Inhibitor							
Efavirenz	600 mg once daily	EBR 50 mg once daily	10	EBR	0.46 (0.36, 0.59)	0.55 (0.41, 0.73)	0.41 (0.28, 0.59)
	600 mg once daily	GZR 200 mg once daily	12	GZR	0.17 (0.13, 0.24)	0.13 (0.09, 0.19)	0.31 (0.25, 0.38)
Raltegravir	25 mg once daily	EBR 50 mg + GZR 200 mg once daily	19	EBR	1.07 (1.00, 1.15)	1.07 (0.99, 1.16)	1.04 (0.98, 1.11)
	25 mg once daily	EBR 50 mg + GZR 200 mg once daily	19	GZR	0.98 (0.89, 1.07)	0.97 (0.83, 1.14)	1.00 (0.93, 1.07)
HIV Nucleotide Reverse Transcriptase Inhibitor							
Tenofovir disoproxil fumarate	300 mg once daily	EBR 50 mg once daily	10	EBR	0.93 (0.82, 1.05)	0.88 (0.77, 1.00)	0.92 (0.81, 1.05)
	300 mg once daily	GZR 200 mg once daily	12	GZR	0.86 (0.65, 1.12)	0.78 (0.51, 1.18)	0.89 (0.78, 1.01)
HIV Fixed Dose Combination Regimen							
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate	150 mg/ 150 mg/ 200 mg/ 300 mg once daily	EBR 50 mg / GZR 100 mg once daily	21	EBR	2.18 (2.02, 2.35)	1.91 (1.77, 2.05)	2.38 (2.19, 2.60)
		EBR 50 mg / GZR 100 mg once daily	21	GZR	5.36 (4.48, 6.43)	4.59 (3.70, 5.69)	2.78 (2.48, 3.11)
Immunosuppressant							
Cyclosporine	400 mg single-dose	EBR 50 mg + GZR 200 mg once daily	14	EBR	1.98 (1.84, 2.13)	1.95 (1.84, 2.07)	2.21 (1.98, 2.47)
	400 mg	EBR 50 mg +	14	GZR	15.21	17.00	3.39

	single-dose	GZR 200 mg + once daily			(12.83, 18.04)	(12.94, 22.34)	(2.82, 4.09)
Mycophenolate mofetil	1000 mg single-dose	EBR 50 mg + GZR 200 mg once daily	14	EBR	1.07 (1.00, 1.14)	1.07 (0.98, 1.16)	1.05 (0.97, 1.14)
	1000 mg single-dose	EBR 50 mg + GZR 200 mg + once daily	14	GZR	0.74 (0.60, 0.92)	0.58 (0.42, 0.82)	0.97 (0.89, 1.06)
Prednisone	40 mg single-dose	EBR 50 mg + GZR 200 mg once daily	14	EBR	1.17 (1.11, 1.24)	1.25 (1.16, 1.35)	1.04 (0.97, 1.12)
	40 mg single-dose	EBR 50 mg + GZR 200 mg once daily	14	GZR	1.09 (0.95, 1.25)	1.34 (1.10, 1.62)	0.93 (0.87, 1.00)
Tacrolimus	2 mg single- dose	EBR 50 mg + GZR 200 mg once daily	16	EBR	0.97 (0.90, 1.06)	0.99 (0.88, 1.10)	0.92 (0.83, 1.02)
	2 mg single- dose	EBR 50 mg + GZR 200 mg once daily	16	GZR	1.12 (0.97, 1.30)	1.07 (0.83, 1.37)	0.94 (0.87, 1.02)
Opioid-Substitution Therapy							
Buprenorphine/ naloxone	8 mg/2 mg single-dose	EBR 50 mg single-dose	15	EBR	1.22 (0.98, 1.52)	1.13 (0.87, 1.46)	1.22 (0.99, 1.51)
	8-24 mg/ 2-6 mg once daily	GZR 200 mg once daily	12	GZR	0.80 (0.53, 1.22)	0.76 (0.40, 1.44)	0.69 (0.54, 0.88)
Methadone	20-120 mg once daily	EBR 50 mg once daily	10	EBR	1.71 (1.16, 2.51)	1.93 (1.30, 2.86)	1.86 (1.22, 2.83)
	20-150 mg once daily	GZR 200 mg once daily	12	GZR	1.03 (0.53, 1.97)	0.88 (0.36, 2.14)	0.77 (0.56, 1.04)
Acid-Reducing Agent							
Famotidine	20 mg single-dose	EBR 50 mg / GZR 100 mg single-dose	16	EBR	1.05 (0.92, 1.18)	1.11 (0.98, 1.26)	1.03 (0.91, 1.17)
	20 mg single-dose	EBR 50 mg/ GZR 100 mg single-dose	16	GZR	1.10 (0.95, 1.28)	0.89 (0.71, 1.11)	1.12 (0.97, 1.30)
Pantoprazole	40 mg once daily	EBR 50 mg / GZR 100 mg single-dose	16	EBR	1.05 (0.93, 1.18)	1.02 (0.92, 1.14)	1.03 (0.92, 1.17)
	40 mg once daily	EBR 50 mg/ GZR 100 mg single-dose	16	GZR	1.12 (0.96, 1.30)	1.10 (0.89, 1.37)	1.17 (1.02, 1.34)
Phosphate Binder							
Calcium acetate	2668 mg single-dose	EBR 50 mg + GZR 100 mg single-dose	12	EBR	0.92 (0.75, 1.14)	0.86 (0.71, 1.04)	0.87 (0.70, 1.09)
	2668 mg single-dose	EBR 50 mg + GZR 100 mg	12	GZR	0.79 (0.68, 0.91)	0.57 (0.40, 0.83)	0.77 (0.61, 0.99)

		single-dose					
Sevelamer carbonate	2400 mg single-dose	EBR 50 mg + GZR 100 mg single-dose	12	EBR	1.13 (0.94, 1.37)	1.07 (0.88, 1.29)	1.22 (1.02, 1.45)
	2400 mg single-dose	EBR 50 mg + GZR 100 mg single-dose	12	GZR	0.82 (0.68, 0.99)	0.53 (0.37, 0.76)	0.84 (0.71, 0.99)
Statin							
Atorvastatin	20 mg single-dose	GZR 200 mg once daily	9	GZR	1.26 (0.97, 1.64)	1.26 (0.83, 1.90)	1.11 (1.00, 1.23)
Pravastatin	40 mg single-dose	EBR 50 mg + GZR 200 mg once daily	12	EBR	0.98 (0.93, 1.02)	0.97 (0.89, 1.05)	0.97 (0.92, 1.02)
	40 mg single-dose	EBR 50 mg + GZR 200 mg once daily	12	GZR	1.24 (1.00, 1.53)	1.42 (1.00, 2.03)	1.07 (0.99, 1.16)
Rosuvastatin	10 mg single-dose	EBR 50 mg + GZR 200 mg single-dose	11	EBR	1.09 (0.98, 1.21)	1.11 (0.99, 1.26)	0.96 (0.86, 1.08)
	10 mg single-dose	GZR 200 mg once daily	11	GZR	1.16 (0.94, 1.44)	1.13 (0.77, 1.65)	0.93 (0.84, 1.03)
	10 mg single-dose	EBR 50 mg + GZR 200 mg once daily	11	GZR	1.01 (0.79, 1.28)	0.97 (0.63, 1.50)	0.95 (0.87, 1.04)
Abbreviations: EBR, elbasvir; GZR, grazoprevir; IV, intravenous; PO, oral; EBR+GZR, administration of EBR and GZR as separate pills; EBR/GZR, administration of EBR and GZR as a single fixed-dose combination tablet							
§AUC _{0-inf} for single-dose, AUC ₀₋₂₄ for once daily							
†AUC ₀₋₂₄							
‡Higher doses of ritonavir have not been tested in a drug interaction study with GZR							

Table 10 - Drug Interactions: Changes in Pharmacokinetics for Co-Administered Drug in the Presence of Elbasvir, Grazoprevir, or Co-Administered Elbasvir and Grazoprevir

Co-Administered Drug	Regimen of Co-Administered Drug	EBR or/and GZR Administration	EBR or/and GZR Regimen	N	Geometric Mean Ratio [90% CI] of Co-Administered Drug PK with/without EBR or/and GZR (No Effect=1.00)		
					AUC [§]	C _{max}	C _{trough} [†]
P-gp Substrate							
Digoxin	Digoxin 0.25 mg single-dose	EBR	50 mg once daily	18	1.11 (1.02, 1.22)	1.47 (1.25, 1.73)	--
CYP3A Substrate							
Midazolam	Midazolam 2 mg single-dose	GZR	200 mg once daily	11	1.34 (1.29, 1.39)	1.15 (1.01, 1.31)	--
CYP2C8 Substrate							
Montelukast	Montelukast 10 mg single-dose	GZR	200 mg once daily	23	1.11 (1.01, 1.20)	0.92 (0.81, 1.06)	1.39 (1.25, 1.56)

HCV Antiviral							
GS-331007	Sofosbuvir 400 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	16	1.13 (1.05, 1.21)	0.87 (0.78, 0.96)	1.53 (1.43, 1.63)
Sofosbuvir	Sofosbuvir 400 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	16	2.43 (2.12, 2.79) [‡]	2.27 (1.72, 2.99)	--
HIV Protease Inhibitor							
Atazanavir/ ritonavir	Atazanavir 300 mg/ ritonavir 100 mg once daily	EBR	50 mg once daily	8	1.07 (0.98, 1.17)	1.02 (0.96, 1.08)	1.15 (1.02, 1.29)
	Atazanavir 300 mg/ ritonavir 100 mg once daily	GZR	200 mg once daily	11	1.43 (1.30, 1.57)	1.12 (1.01, 1.24)	1.23 (1.13, 1.34)
Darunavir/ ritonavir	Darunavir 600 mg/ ritonavir 100 mg twice daily	EBR	50 mg once daily	8	0.95 (0.86, 1.06)	0.95 (0.85, 1.05)	0.94 (0.85, 1.05)
	Darunavir 600 mg/ ritonavir 100 mg twice daily	GZR	200 mg once daily	13	1.11 (0.99, 1.24)	1.10 (0.96, 1.25)	1.00 (0.85, 1.18)
Lopinavir/ ritonavir	Lopinavir 400 mg/ ritonavir 100 mg twice daily	EBR	50 mg once daily	9	1.02 (0.93, 1.13)	1.02 (0.92, 1.13)	1.07 (0.97, 1.18)
	Lopinavir 400 mg/ ritonavir 100 mg twice daily	GZR	200 mg once daily	13	1.03 (0.96, 1.16)	0.97 (0.88, 1.08)	0.97 (0.81, 1.15)
HIV Integrase Strand Transfer Inhibitor							
Dolutegravir	Dolutegravir 50 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	12	1.16 (1.00, 1.34)	1.22 (1.05, 1.40)	1.14 (0.95, 1.36)
Raltegravir	Raltegravir 400 mg single-dose	EBR	50 mg single-dose	10	1.02 (0.81, 1.27)	1.09 (0.83, 1.44)	0.99 (0.80, 1.22) [§]
	Raltegravir 400 mg twice daily	GZR	200 mg once daily	11	1.43 (0.89, 2.30)	1.46 (0.78, 2.73)	1.47 (1.08, 2.00)
HIV Non-Nucleoside Reverse Transcriptase Inhibitor							
Efavirenz	Efavirenz 600 mg once daily	EBR	50 mg once daily	7	0.82 (0.78, 0.86)	0.74 (0.67, 0.82)	0.91 (0.87, 0.96)
	Efavirenz 600 mg once daily	GZR	200 mg once daily	11	1.00 (0.96, 1.05)	1.03 (0.99, 1.08)	0.93 (0.88, 0.98)
Rilpivirine	Rilpivirine 25 mg once	EBR + GZR	50 mg + 200 mg once daily	19	1.13	1.07	1.16

	daily				(1.07, 1.20)	(0.97, 1.17)	(1.09, 1.23)
HIV Nucleotide Reverse Transcriptase Inhibitor							
Tenofovir disoproxil fumarate	Tenofovir disoproxil fumarate 300 mg once daily	EBR	50 mg once daily	10	1.34 (1.23, 1.47)	1.47 (1.32, 1.63)	1.29 (1.18, 1.41)
	Tenofovir disoproxil fumarate 300 mg once daily	GZR	200 mg once daily	12	1.18 (1.09, 1.28)	1.14 (1.04, 1.25)	1.24 (1.10, 1.39)
	Tenofovir disoproxil fumarate 300 mg once daily	EBR + GZR	50 mg + 100 mg once daily	13	1.27 (1.20, 1.35)	1.14 (0.95, 1.36)	1.23 (1.09, 1.40)
HIV Fixed Dose Combination Regimen							
Elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil fumarate	Elvitegravir 150 mg once daily	EBR / GZR	50 mg / 100 mg once daily	22	1.10 (1.00, 1.21)	1.02 (0.93, 1.11)	1.31 (1.11, 1.55)
	Cobicistat 150 mg once daily	EBR / GZR	50 mg / 100 mg once daily	22	1.49 (1.42, 1.57)	1.39 (1.29, 1.50)	--
	Emtricitabine 200 mg once daily	EBR / GZR	50 mg / 100 mg once daily	22	1.07 (1.03, 1.10)	0.96 (0.90, 1.02)	1.19 (1.13, 1.25)
	Tenofovir disoproxil fumarate 300 mg once daily	EBR / GZR	50 mg / 100 mg once daily	22	1.18 (1.13, 1.24)	1.25 (1.14, 1.37)	1.20 (1.15, 1.26)
Immunosuppressant							
Cyclosporine	Cyclosporine 400 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	14	0.96 (0.90, 1.02)	0.90 (0.85, 0.97)	1.00 (0.92, 1.08) [§]
Mycophenolic acid	Mycophenolate mofetil 1000 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	14	0.95 (0.87, 1.03)	0.85 (0.67, 1.07)	--
Prednisolone	Prednisone 40 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	14	1.08 (1.01, 1.16)	1.04 (0.99, 1.09)	--
Prednisone	Prednisone 40 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	14	1.08 (1.00, 1.17)	1.05 (1.00, 1.10)	--
Tacrolimus	Tacrolimus 2 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	16	1.43 (1.24, 1.64)	0.60 (0.52, 0.69)	1.70 (1.49, 1.94) [§]

Oral Contraceptive							
Ethinyl estradiol (EE)	0.03 mg EE/ 0.15 mg LNG single-dose	EBR	50 mg once daily	20	1.01 (0.97, 1.05)	1.10 (1.05, 1.16)	--
		GZR	200 mg once daily	20	1.10 (1.05, 1.14)	1.05 (0.98, 1.12)	--
Levonorgestrel (LNG)		EBR	50 mg once daily	20	1.14 (1.04, 1.24)	1.02 (0.95, 1.08)	--
		GZR	200 mg once daily	20	1.23 (1.15, 1.32)	0.93 (0.84, 1.03)	--
Opioid Substitution Therapy							
Buprenorphine	Buprenorphine 8 mg/Naloxone 2 mg single-dose	EBR	50 mg once daily	15	0.98 (0.89, 1.08)	0.94 (0.82, 1.08)	0.98 (0.88, 1.09)
	Buprenorphine 8-24 mg/Naloxone 2-6 mg once daily	GZR	200 mg once daily	12	0.98 (0.81, 1.19)	0.90 (0.76, 1.07)	--
R-Methadone	Methadone 20-120 mg once daily	EBR	50 mg once daily	10	1.03 (0.92, 1.15)	1.07 (0.95, 1.20)	1.10 (0.96, 1.26)
	Methadone 20-150 mg once daily	GZR	200 mg once daily	12	1.09 (1.02, 1.17)	1.03 (0.96, 1.11)	
S-Methadone	Methadone 20-120 mg once daily	EBR	50 mg once daily	10	1.09 (0.94, 1.26)	1.09 (0.95, 1.25)	1.20 (0.98, 1.47)
	Methadone 20-150 mg once daily	GZR	200 mg once daily	12	1.23 (1.12, 1.35)	1.15 (1.07, 1.25)	--
Statin							
Atorvastatin	Atorvastatin 10 mg single-dose	EBR + GZR	50 mg once + 200 mg daily	16	1.94 (1.63, 2.33)	4.34 (3.10, 6.07)	0.21 (0.17, 0.26)
	Atorvastatin 20 mg single-dose	GZR	200 mg once daily	9	3.00 (2.42, 3.72)	5.66 (3.39, 9.45)	--
Pravastatin	Pravastatin 40 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	12	1.33 (1.09, 1.64) [†]	1.28 (1.05, 1.55)	--
Rosuvastatin	Rosuvastatin 10 mg single-dose	EBR + GZR	50 mg + 200 mg once daily	12	2.26 (1.89, 2.69) [#]	5.49 (4.29, 7.04)	0.98 (0.84, 1.13)
		GZR	200 mg once daily	12	1.59 (1.33, 1.89) [#]	4.25 (3.25, 5.56)	0.80 (0.70, 0.91)
Abbreviations: EBR, elbasvir; GZR, grazoprevir; EBR+GZR, administration of EBR and GZR as separate tablets; EBR/GZR, administration of EBR and GZR as a single fixed-dose combination tablet							

[§]AUC_{0-inf} for single-dose administration; AUC₀₋₂₄ for once daily administration; AUC₀₋₁₂ for twice daily administration

[†]C₂₄ for once daily administration; C₁₂ for twice daily administration

[‡]N=14

[§]C₁₂

[¶]N=10

[#]N=8

Drug-Food Interactions

ZEPATIER[®] can be taken with or without food.

Drug-Herb Interactions

Co-administration of ZEPATIER[®] with St. John's wort (*Hypericum perforatum*) is contraindicated.

Drug-Laboratory Interactions

Interactions with clinical laboratory tests have not been established.

DOSAGE AND ADMINISTRATION

Dosing Considerations

Since ZEPATIER[®] is a fixed dose combination product, an adjustment of its recommended dose is not possible.

Recommended Dose Regimens in Adults

ZEPATIER[®] is a two-drug, fixed-dose combination product containing 50 mg of elbasvir and 100 mg of grazoprevir in a single tablet. The recommended dosage of ZEPATIER[®] is one tablet taken orally once daily with or without food (see **Table 11 and ACTION AND CLINICAL PHARMACOLOGY**). Dose adjustment cannot be made for this fixed dose combination.

Treatment Regimen and Duration of Therapy

Table 11 below provides the recommended ZEPATIER[®] treatment regimen and duration based on the patient population and genotype in HCV mono-infected.

Table 11 - Recommended Dosage Regimens and Durations for ZEPATIER[®] for Treatment of Chronic Hepatitis C Infection in Patients with or without Cirrhosis

Treatment ^b	Duration
Genotype 1 or 4 TN^{&} or PR-TE^β Relapsers; Genotype 1 PI/PR-TE* Relapsers	
ZEPATIER [®]	12 weeks <i>(8 weeks may be considered in treatment-naïve genotype 1b[†] patients without significant fibrosis or cirrhosis[‡])</i>
Genotype 1 PR-TE or PI/PR-TE On-Treatment Virologic Failures[§] Genotype 4 PR-TE On-Treatment Virologic Failures	
Genotype 1b [†] (PR-TE or PI/PR-TE) ZEPATIER [®]	12 weeks
Genotype 1a (PR-TE or PI/PR-TE), or Genotype 4 (PR-TE) ZEPATIER [®] with ribavirin ^{¶, #}	16 weeks
Genotype 3 TN	
ZEPATIER [®] with sofosbuvir [§]	12 weeks
^b Refer to the product monograph of the medicinal products that are used in combination with ZEPATIER [®] for specific dosing instructions. ^{&} TN: Treatment-naïve. ^β PR-TE: Patients who failed treatment with peginterferon alfa + ribavirin. [*] PI/PR-TE: Patients who failed peginterferon alfa + ribavirin + boceprevir, simeprevir, or telaprevir. [†] Includes patients with known genotype 1 subtypes other than 1a or 1b. [‡] Patients without clinically significant fibrosis or cirrhosis as determined by liver biopsy (i.e., METAVIR F0-F2) or by non-invasive tests. [§] On-treatment virologic failures are patients who have had a null response, partial response, virologic breakthrough or rebound, or intolerance to prior treatment. [¶] In clinical trials, the dose of ribavirin was weight-based (<66 kg = 800 mg/day, 66 to 80 kg = 1000 mg/day, 81 to 105 kg = 1200 mg/day, >105 kg = 1400 mg/day) administered in two divided doses with food. For further information on ribavirin dosing and dose modifications, refer to the ribavirin prescribing information. [#] Patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] <30 mL/min/1.73 m ²) or with end stage renal disease (ESRD) should receive ZEPATIER [®] 12 weeks without ribavirin (See DOSAGE AND ADMINISTRATION, Severe Renal Impairment and ESRD). [§] See Severe Renal impairment and end stage renal disease (ESRD).	

HCV/HIV 1 Co infection

Safety and efficacy of ZEPATIER[®] have been established in HIV-1 co-infected treatment-naïve HCV genotype 1 and 4 patients as well as treatment-experienced HCV genotype 1 patients. Dosing recommendation for these patients is same as in Table 11.

Severe Renal Impairment and ESRD

In genotype 1 patients with severe renal impairment (eGFR) < 30 mL/min/1.73m²) or with ESRD, including patients on hemodialysis, administer ZEPATIER[®] without ribavirin according to the treatment durations in Table 11 (see **WARNINGS AND PRECAUTIONS, Special**

Populations). For treatment-experienced genotype 1a patients with prior on-treatment virologic failure and severe renal impairment or with ESRD, 12 weeks without ribavirin treatment duration of ZEPATIER[®] may be considered (see **CLINICAL TRIALS**).

The safety and efficacy of ZEPATIER[®] in genotype 4 patients as well as ZEPATIER[®] with sofosbuvir in genotype 3 patients with severe renal impairment (eGFR) <30 mL/min/1.73m²) or with ESRD, including patients on hemodialysis have not been established.

Hepatic Impairment

ZEPATIER[®] may be used as recommended in patients with mild hepatic impairment (Child-Pugh A). ZEPATIER[®] is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B and C) due to the expected significant increase in grazoprevir plasma concentration (see **CONTRAINDICATIONS, WARNING AND PRECAUTIONS, Hepatic, and ACTION AND CLINICAL PHARMACOLOGY**).

The safety and efficacy of ZEPATIER[®] have not been established in patients awaiting liver transplant or in liver transplant recipients. The plasma concentration of grazoprevir is increased if ZEPATIER[®] is co-administered with cyclosporine. Co-administration with cyclosporine is contraindicated (see **CONTRAINDICATIONS**).

HCV/HBV (Hepatitis B Virus) co-infection

The safety and efficacy of ZEPATIER[®] have not been studied in HCV/HBV co-infected patients.

Missed Dose

In case a dose of ZEPATIER[®] is missed and it is within 16 hours of the time ZEPATIER[®] is usually taken, the patient should be instructed to take ZEPATIER[®] as soon as possible and then take the next dose of ZEPATIER[®] at the usual time. If more than 16 hours have passed since ZEPATIER[®] is usually taken, then the patient should be instructed that the missed dose should NOT be taken and to take the next dose per the usual dosing schedule. Patients should be instructed not to take a double dose.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Human experience of overdose with ZEPATIER[®] is limited. No specific antidote is available for overdose with ZEPATIER[®]. In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted.

Hemodialysis does not remove elbasvir or grazoprevir since elbasvir and grazoprevir are highly bound to plasma protein (see **ACTION AND CLINICAL PHARMACOLOGY**).

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action

Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor

ZEPATIER[®] is a fixed-dose combination of elbasvir and grazoprevir which are direct-acting antiviral agents against the hepatitis C virus (see **MICROBIOLOGY**).

Pharmacodynamics

Cardiac Electrophysiology

Thorough QT studies have been conducted for elbasvir and grazoprevir.

The effect of elbasvir 700 mg on the QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 42 healthy subjects. At a plasma concentration 3 to 4 times the plasma therapeutic concentration, elbasvir does not prolong QTc to any clinically relevant extent.

The effect of grazoprevir 1600 mg on QTc interval was evaluated in a randomized, single-dose, placebo- and active-controlled (moxifloxacin 400 mg) 3-period crossover thorough QT trial in 41 healthy subjects. At a plasma concentration 40 times the therapeutic plasma concentration, grazoprevir does not prolong QTc to any clinically relevant extent.

Pharmacokinetics

Table 12 - Summary of ZEPATIER[®]'s Pharmacokinetic Parameters in Non-Cirrhotic, HCV-Infected Subjects

	C_{max}	AUC _{0-24h}
Elbasvir		
Steady-state geometric mean	137 nM	2180 nM•hr
Grazoprevir		
Steady-state geometric mean	220 nM	1860 nM•hr

The pharmacokinetic properties of elbasvir and grazoprevir have been evaluated in non-HCV-infected adult subjects and in HCV-infected adult subjects. Elbasvir pharmacokinetics were similar in healthy subjects and HCV-infected subjects and were approximately dose-proportional over the range of 5-100 mg once daily. Grazoprevir oral exposures are approximately 2-fold greater in HCV-infected subjects as compared to healthy subjects. Grazoprevir pharmacokinetics increased in a greater than dose-proportional manner over the range of 10-800 mg once daily in HCV-infected subjects. Ribavirin or sofosbuvir co-administration with ZEPATIER[®] had no clinically relevant impact on plasma AUC and C_{max} of elbasvir and grazoprevir compared to administration of ZEPATIER[®] alone. Following once daily administration of ZEPATIER[®] to HCV-infected subjects, elbasvir and grazoprevir reached steady state within approximately 6 days.

Absorption:

Following administration of ZEPATIER[®] to HCV-infected subjects, elbasvir peak plasma concentrations occur at a median T_{max} of 3 hours (range of 3 to 6 hours); grazoprevir peak plasma concentrations occur at a median T_{max} of 2 hours (range of 30 minutes to 3 hours). The absolute bioavailability of elbasvir is estimated to be 32%, and grazoprevir is estimated to be 10 to 40%.

Effect of Food

Relative to fasting conditions, the administration of a single dose of ZEPATIER[®] with a high-fat (900 kcal, 500 kcal from fat) meal to healthy subjects resulted in decreases in elbasvir AUC_{0-inf} and C_{max} of approximately 11% and 15%, respectively, and increases in grazoprevir AUC_{0-inf} and C_{max} of approximately 1.5-fold and 2.8-fold, respectively. These differences in elbasvir and grazoprevir exposure are not clinically relevant; therefore, ZEPATIER[®] may be taken without regard to food.

Distribution:

Elbasvir and grazoprevir are extensively bound (>99.9% and 98.8%, respectively) to human plasma proteins. Both elbasvir and grazoprevir bind to human serum albumin and α 1-acid glycoprotein. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.

In preclinical distribution studies, elbasvir distributed into most tissues including the liver and grazoprevir distributed predominantly to the liver.

Metabolism:

Elbasvir and grazoprevir are partially eliminated by oxidative metabolism, primarily by CYP3A. No circulating metabolites of either elbasvir or grazoprevir were detected in human plasma.

Elimination:

The geometric mean apparent terminal half-life (% geometric mean coefficient of variation) is approximately 24 (24%) hours at 50 mg elbasvir and approximately 31 (34%) hours at 100 mg grazoprevir and in HCV-infected subjects.

The primary route of elimination of elbasvir and grazoprevir is through feces with almost all (>90%) of radiolabeled dose recovered in feces compared to <1% in urine.

Special Populations and Conditions**Pediatrics:**

The pharmacokinetics of ZEPATIER[®] in pediatric patients less than 18 years of age have not been established.

Geriatrics:

In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 16% and 45% higher, respectively, in \geq 65-years of age compared to subjects less than 65 years of age. No dose adjustment of ZEPATIER[®] is recommended based on age (see **WARNINGS AND PRECAUTIONS, Special Populations**).

Gender:

In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 50% and 30% higher, respectively, in females compared to males. No dose adjustment of ZEPATIER[®] is recommended based on sex.

Weight/BMI:

In population pharmacokinetic analyses, there was no effect of weight on elbasvir pharmacokinetics. Grazoprevir AUC is estimated to be 15% higher in a 53 kg subject compared to a 77 kg subject. This change is not clinically relevant for grazoprevir. Therefore, no dose adjustment of ZEPATIER[®] is recommended based on weight/BMI.

Race/Ethnicity:

In population pharmacokinetic analyses, elbasvir and grazoprevir AUCs are estimated to be 15% and 50% higher, respectively, for Asians compared to Whites. Population pharmacokinetics estimates of exposure of elbasvir and grazoprevir were comparable between Whites and Black/African Americans. No dose adjustment of ZEPATIER[®] is recommended based on race/ethnicity.

Hepatic Insufficiency:

The pharmacokinetics of elbasvir and grazoprevir were evaluated in non-HCV-infected subjects with mild hepatic impairment (Child-Pugh Category A [CP-A], score of 5-6), moderate hepatic impairment (Child-Pugh Category B [CP-B], score of 7-9) and severe hepatic impairment (Child-Pugh Category C [CP-C], score of 10-15). In addition, the pharmacokinetics of elbasvir and grazoprevir were also evaluated in HCV-infected subjects with mild hepatic impairment (CP-A) or moderate hepatic impairment (CP-B).

Elbasvir AUC_{0-inf} was decreased by 40% in non-HCV-infected subjects with mild hepatic impairment (CP-A) compared to matching healthy subjects. In non-HCV-infected subjects with mild hepatic impairment, grazoprevir steady-state AUC₀₋₂₄ was increased 70% compared to matching healthy subjects. Population PK analyses of HCV-infected subjects in Phase 2 and 3 studies demonstrated that elbasvir steady-state AUC was similar in HCV-infected subjects with mild hepatic impairment compared to subjects without hepatic impairment. Grazoprevir steady-state AUC₀₋₂₄ increased by approximately 65% in HCV-infected subjects with compensated cirrhosis compared to HCV-infected, non-cirrhotic subjects.

Elbasvir AUC decreased by 28% in non-HCV-infected subjects with moderate hepatic impairment (CP-B) compared to matched healthy subjects. Elbasvir steady-state AUC was similar in HCV-infected subjects with moderate hepatic impairment compared to subjects without hepatic impairment. Compared to healthy matched subjects, grazoprevir steady-state AUC₀₋₂₄ was increased 5-fold in non-HCV-infected subjects with moderate hepatic impairment. ZEPATIER[®] is contraindicated in HCV-infected subjects with moderate hepatic impairment (CP-B) due to lack of clinical safety and efficacy experience in this population and the expected increase in grazoprevir exposure.

Elbasvir AUC_{0-inf} is decreased by 12% in non-HCV-infected subjects with severe hepatic impairment (CP-C) compared to matching healthy subjects. Grazoprevir steady-state AUC₀₋₂₄ was increased 12-fold in non-HCV-infected subjects with severe hepatic impairment compared to healthy matched subjects. ZEPATIER[®] is contraindicated in HCV-infected subjects with severe hepatic impairment (CP-C) based on the significant increase in grazoprevir exposure observed in non-HCV-infected subjects with severe hepatic impairment (see **CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS, Special Populations**).

Renal Insufficiency:

The pharmacokinetics of elbasvir and grazoprevir were evaluated in non-HCV-infected subjects with severe renal impairment (eGFR < 30 mL/min/1.73 m²) with or without hemodialysis and also in HCV-infected subjects with severe renal impairment with or without hemodialysis. Elbasvir and grazoprevir are not expected to be removed by peritoneal dialysis as both are highly protein bound.

Relative to non-HCV-infected subjects with normal renal function (eGFR >80 mL/min/1.73 m²), elbasvir and grazoprevir AUC values were increased by 86% and 65%, respectively, in non-HCV-infected subjects with severe renal impairment who were not on hemodialysis. Relative to subjects with normal renal function, elbasvir and grazoprevir AUC values were unchanged in non-HCV-infected subjects with hemodialysis-dependent, severe renal impairment. Elbasvir and grazoprevir are highly bound to plasma protein. Elbasvir and grazoprevir are not removed by hemodialysis. Concentrations of elbasvir were not quantifiable in the dialysate samples. Less than 0.5% of grazoprevir was recovered in dialysate over a 4-hour hemodialysis session. Elbasvir and grazoprevir are not expected to be removed by peritoneal dialysis.

In population pharmacokinetic analysis, elbasvir AUC was 25% higher in hemodialysis-dependent subjects and 46% higher in non-hemodialysis-dependent subjects with severe renal impairment compared to elbasvir AUC in subjects without severe renal impairment. In population pharmacokinetic analysis in HCV-infected subjects, grazoprevir AUC was 10% higher in hemodialysis-dependent subjects and 40% higher in non-hemodialysis-dependent subjects with severe renal impairment compared to grazoprevir AUC in subjects without severe renal impairment.

Overall, changes in exposure of elbasvir and grazoprevir in HCV-infected subjects with renal impairment with or without hemodialysis are not clinically relevant. (see **WARNINGS AND PRECAUTIONS, Special Populations**).

STORAGE AND STABILITY

Store at room temperature (15°C - 30°C) in the original package.

Store ZEPATIER[®] in the original blister package until use to protect from moisture.

SPECIAL HANDLING INSTRUCTIONS

No special requirements.

Any unused product or waste material should be disposed of in accordance with local requirements.

DOSAGE FORMS, COMPOSITION AND PACKAGING

Dosage Forms

ZEPATIER[®] (elbasvir and grazoprevir) is a fixed-dose combination tablet containing 50 mg of elbasvir and 100 mg of grazoprevir and for oral administration. The film-coated tablets are beige-colored, oval-shaped, debossed with “770” on one side and plain on the other. They are available in two blister packages totaling 28 tablets.

Composition

ZEPATIER[®] film-coated tablets contain 50 mg of elbasvir and 100 mg of grazoprevir).

Non-medicinal ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, and vitamin E polyethylene glycol succinate.

The tablets are film-coated with a coating material containing the following inactive ingredients: carnauba wax, ferrousferic oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide and triacetin.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

ZEPATIER[®] (elbasvir and grazoprevir) tablets

Drug Substance

Elbasvir:

Proper name:

elbasvir


Chemical name:

Dimethyl *N,N'*-([(6*S*)-6-phenylindolo[1,2-*c*][1,3]benzoxazine-3,10-diyl]bis {1*H*-imidazole-5,2-diyl-(2*S*)-pyrrolidine-2,1-diyl}[(2*S*)-3-methyl-1-oxobutane-1,2-diyl])dicarbamate.

Molecular formula and molecular mass:

C₄₉H₅₅N₉O₇; 882.02

Structural formula:



Physicochemical properties:

Elbasvir is practically insoluble in water (<0.1 mg/mL) and very slightly soluble in ethanol (0.2 mg/mL), but is very soluble in ethyl acetate and acetone.

Grazoprevir:

Proper name:


grazoprevir

Chemical name:

1*aR*,5*S*,8*S*,10*R*,22*aR*)-*N*-[(1*R*,2*S*)-1-[(Cyclopropylsulfonamido)carbonyl]-2-ethenylcyclopropyl]-14-methoxy-5-(2-methylpropan-2-yl)-3,6-dioxo-1,1*a*,3,4,5,6,9,10,18,19,20,21,22,22*a*-tetradecahydro-8*H*-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-*b*]quinoxaline-8-carboxamide.

Molecular formula and molecular mass: C₃₈H₅₀N₆O₉S; 766.90

Structural formula:



Physicochemical properties:

Grazoprevir is practically insoluble in water (< 0.1 mg/mL) but is freely soluble in ethanol and some organic solvents (e.g., acetone, tetrahydrofuran and N,N-dimethylformamide).

CLINICAL TRIALS

Overview of Clinical Trials

The safety and efficacy of ZEPATIER[®] (elbasvir + grazoprevir FDC) were evaluated in 8 clinical trials in approximately 1800 subjects with genotype (GT) 1, 3, or 4 chronic hepatitis C (CHC) infection with compensated liver disease (with and without cirrhosis).

An overview of the trials is provided in Table 13.

Table 13 - Summary of Clinical Trial Designs in Treatment of Chronic Hepatitis C Infection

Trial	Population	Study Arms and Duration (Number of Subjects Treated)	Trial Design
C-EDGE TN (P060)	GT 1, 4 TN with or without cirrhosis	<ul style="list-style-type: none"> • ZEPATIER[®] for 12 weeks (N=306) • Pbo for 12 weeks (N=105) 	Randomized, double-blind, Pbo-controlled trial in TN subjects with GT 1, or 4 infection with or without cirrhosis. Subjects were randomized in a 3:1 ratio to: ZEPATIER [®] for 12 weeks (ITG) or Pbo for 12 weeks followed by open-label treatment with ZEPATIER [®] for 12 weeks (DTG).
C-EDGE COINFECTION (P061)	GT 1, 4 TN with or without cirrhosis HCV/HIV-1 co-infection	<ul style="list-style-type: none"> • ZEPATIER[®] for 12 weeks (N=217) 	Open-label trial in TN HCV/HIV-1 co-infected subjects with GT 1, or 4 infection with or without cirrhosis. Subjects received ZEPATIER [®] for 12 weeks.
C-SURFER (P052)	GT 1 TN or TE with or without cirrhosis Chronic Kidney Disease	<ul style="list-style-type: none"> • EBR[†]+GZR[†] for 12 weeks (N=122) • Pbo for 12 weeks (N=113) 	Randomized, double-blind, Pbo-controlled trial in subjects with GT 1 infection, with or without cirrhosis, with CKD Stage 4 (eGFR 15-29 mL/min/1.73 m ²) or Stage 5 (eGFR < 15 mL/min/1.73 m ²), including subjects on hemodialysis, who were TN or who had failed prior therapy with IFN or peg-IFN ± RBV therapy. Subjects were randomized in a 1:1 ratio to one of the following treatment groups: EBR + GZR for 12 weeks (ITG) or Pbo for 12 weeks followed by open-label treatment with ZEPATIER [®] for 12 weeks (DTG). In addition, 11 subjects received open-label EBR + GZR for 12 weeks (intensive PK arm).
C-WORTHY (P035)	GT 1, 3 TN with or without cirrhosis TE Null Responder with or without cirrhosis TN HCV/HIV-1 co-infection without cirrhosis	<ul style="list-style-type: none"> • EBR[†]+GZR[†] for 8, 12, or 18 weeks (N=31, 136, and 63, respectively) • EBR[†]+GZR[†]+RBV[†] for 8, 12, or 18 weeks (N=60, 152 and 65, respectively) 	Multi-arm, multi-stage, randomized, open-label trial which included subjects with GT 1 or 3 infection who were TN or who had failed prior therapy with peg-IFN ± RBV therapy. In the stage evaluating shorter duration of therapy in subjects with GT 1b infection without cirrhosis, subjects were randomized in a 1:1 ratio to EBR + GZR with or without RBV for 8 weeks. In the stage evaluating subjects with GT 3 infection without cirrhosis who were TN, subjects were randomized to EBR + GZR with RBV for 12 or 18 weeks. In the other stages, subjects with GT 1 infection with or without cirrhosis who were TN (with or without HCV/HIV-1 co-infection) or who were

			peg-IFN + RBV null responders, were randomized to EBR + GZR with or without RBV for 8, 12 or 18 weeks.
C-SCAPE (P047)	GT 4 TN without cirrhosis	<ul style="list-style-type: none"> • EBR[¶]+GZR[¶] for 12 weeks (N=10) • EBR[¶] + GZR[¶] + RBV[†] for 12 weeks (N=10) 	Randomized, open-label trial which included TN subjects with genotype 4 infection without cirrhosis. Subjects were randomized in a 1:1 ratio to EBR + GZR for 12 weeks or EBR + GZR + RBV for 12 weeks
C-EDGE TE (P068)	GT 1, 4 TE with or without cirrhosis with or without HCV/HIV-1 co-infection	<ul style="list-style-type: none"> • ZEPATIER[®] for 12 or 16 weeks (N=105, and 101, respectively) • ZEPATIER[®] + RBV[†] for 12 or 16 weeks (N=104 and 104, respectively) 	Randomized, open-label trial in subjects with GT 1, or 4 infection, with or without cirrhosis, with or without HCV/HIV-1 co-infection, who had failed prior therapy with peg-IFN + RBV therapy. Subjects were randomized in a 1:1:1:1 ratio to one of the following treatment groups: ZEPATIER [®] for 12 weeks, ZEPATIER [®] + RBV for 12 weeks, ZEPATIER [®] for 16 weeks, or ZEPATIER [®] + RBV for 16 weeks.
C-SALVAGE (P048)	GT 1 TE with HCV protease inhibitor regimen [‡] with or without cirrhosis	<ul style="list-style-type: none"> • EBR[¶] + GZR[¶] + RBV[†] for 12 weeks (N=79) 	Open-label trial in subjects with GT 1 infection, with or without cirrhosis, who had failed prior treatment with boceprevir, simeprevir, or telaprevir in combination with peg-IFN + RBV. Subjects received EBR + GZR + RBV for 12 weeks.
C-SWIFT (P074)	GT 1, 3 TN with or without cirrhosis	<ul style="list-style-type: none"> • ZEPATIER[®] + sofosbuvir[§] for 8 or 12 weeks in GT 3 (N= 15 and N=26, respectively) • ZEPATIER[®] + sofosbuvir[§] for 4, 6 or 8 weeks in GT 1 (N=31, 50, and 21, respectively) 	Open-label trial of ZEPATIER [®] + sofosbuvir in subjects with GT 1 or 3 infection. Non-cirrhotic GT 3 infected subjects, were randomized (1:1) to 8 or 12 weeks of treatment, and cirrhotic GT 3 infected subjects received 12 weeks of treatment. Non-cirrhotic GT 1 infected subjects, were randomized (1:1) to 4 or 6 weeks of treatment, and cirrhotic GT 1 infected subjects were randomized (1:1) to 6 or 8 weeks of treatment.
<p>GT = Genotype TN = Treatment-Naïve TE = Treatment-Experienced (failed prior treatment with interferon [IFN] or peginterferon alfa [peg-IFN] with or without ribavirin (RBV) or were intolerant to prior therapy) ITG = Immediate Treatment Group DTG = Delayed Treatment Group CKD = Chronic Kidney Disease Pbo = Placebo [¶] EBR = elbasvir 50 mg; GZR = grazoprevir 100 mg; EBR+GZR = co-administered as single agents [†] RBV was administered at a total daily dose of 800 mg to 1400 mg based on weight (see DOSAGE AND ADMINISTRATION) [‡] Failed prior treatment with boceprevir, telaprevir, or simeprevir in combination with peg-IFN + RBV [§] Sofosbuvir dose was 400 mg once a day</p>			

Sustained virologic response was the primary endpoint in all trials and was defined as HCV RNA less than lower limit of quantification (LLOQ) at 12 weeks after the cessation of treatment (SVR). Serum HCV RNA values were measured during these clinical trials using the COBAS AmpliPrep/COBAS Taqman HCV test (version 2.0) with an LLOQ of 15 HCV RNA IU/mL,

with the exception of C-WORTHY and C-SCAPE where the assay had an LLOQ of 25 HCV RNA IU/mL.

Clinical Trials in Treatment-Naïve Subjects with Genotype 1, or 4 Chronic Hepatitis C Infection

Demographic and baseline characteristics for treatment-naïve subjects with genotype 1, or 4 CHC infection treated with ZEPATIER® for 12 weeks in C-EDGE TN, C-EDGE COINFECTION, C-SURFER, C-WORTHY, and C-SCAPE are provided in Table 14.

Table 14 -Demographic and Baseline Characteristics of Treatment-Naïve Subjects with or without Cirrhosis Treated with ZEPATIER® for 12 Weeks, with Genotype 1 or 4 Chronic Hepatitis C Infection

Trial	C-EDGE TN (P060)	C-EDGE COINFECTION (HCV/HIV-1 Co-Infection) (P061)	C-SURFER (CKD Stages 4-5, including hemodialysis) (P052)	C-WORTHY (P035)	C-SCAPE (P047)	All Studies
Regimen	ZEPATIER® 12 Weeks N=306 n (%)	ZEPATIER® 12 Weeks N=217 n (%)	EBR + GZR 12 Weeks N=101 n (%)	EBR + GZR 12 Weeks N=103 n (%)	EBR + GZR 12 Weeks N=10 n (%)	N=737 n (%)
Characteristics						
Age (Years)						
Mean (SD)	52 (11)	49 (9)	57 (9)	51 (12)	45 (7)	52 (11)
Gender						
Male	168 (55)	182 (84)	74 (73)	66 (64)	6 (60)	496 (67)
Race						
White	190 (62)	166 (76)	51 (50)	88 (85)	8 (80)	503 (68)
Black or African American	59 (19)	38 (18)	46 (46)	10 (10)	1 (10)	154 (21)
Asian	45 (15)	6 (3)	3 (3)	2 (2)	1 (10)	57 (8)
Other	12 (4)	7 (3)	1 (<1)	3 (3)	0 (0)	23 (3)
IL28B Genotype						
CC	98 (32)	77 (35)	26 (26)	26 (25)	3 (30)	230 (31)
Non-CC	206 (67)	140 (65)	73 (72)	77 (75)	7 (70)	503 (68)
Unknown	2 (<1)	0 (0)	2 (2)	0 (0)	0 (0)	4 (<1)
HCV Genotype						
1a	157 (51)	144 (66)	53 (52)	72 (70)	0 (0)	426 (58)
1b	131 (43)	44 (20)	48 (48)	29 (28)	0 (0)	252 (34)
1-Other	0 (0)	1 (<1)	0 (0)	2 (2)	0 (0)	3 (<1)
4	18 (6)	28 (13)	0 (0)	0 (0)	10 (100)	56 (8)
Baseline HCV RNA						
>800,000 IU/mL	215 (70)	127 (59)	56 (55)	85 (83)	7 (70)	490 (66)
Cirrhosis Status*						
Non-Cirrhotic	236 (77)	182 (84)	97 (96)	74 (72)	10 (100)	599 (81)
Cirrhotic	70 (23)	35 (16)	4 (4)	29 (28)	0 (0)	138 (19)

Hepatic Fibrosis Stage (METAVIR Score)^{†*}						
F0 to F2	201 (66)	159 (73)	74 (73)	66 (64)	10 (100)	510 (69)
F3	35 (11)	23 (11)	11 (11)	8 (8)	0 (0)	77 (10)
F4	70 (23)	35 (16)	4 (4)	29 (28)	0 (0)	138 (19)
HCV/HIV Co-Infected	0 (0)	217 (100)	0 (0)	30 (29)	0 (0)	247 (34)

[†]By liver biopsy or by non-invasive tests.

*12 subjects in C-SURFER with incomplete fibrosis data are counted as non cirrhotic and are not included in hepatic fibrosis stage.

Study results

Table 15 presents treatment outcomes for ZEPATIER[®] in treatment-naïve subjects from C-EDGE TN, C-EDGE COINFECTION, C-SURFER, C-WORTHY, and C-SCAPE trials and from the pooled data from these trials. In trials C-EDGE TN and C-SURFER, the treatment outcomes for subjects treated with ZEPATIER[®] in the immediate treatment groups and intensive PK arm are presented. In the C-WORTHY and C-SCAPE trials, the addition of RBV to the regimens was not shown to improve the treatment outcomes. Therefore, only the 12 weeks treatment arms without RBV are presented in Table 15.

Table 15 - Treatment Outcomes after 12 Weeks of Treatment in Treatment-Naïve Subjects with or without Cirrhosis, with Genotype 1 or 4 Chronic Hepatitis C Infection

Trial	C-EDGE TN (P060)	C-EDGE COINFECTION (HCV/HIV-1 Co-Infection) (P061)	C-SURFER (CKD Stages 4-5, including hemodialysis) (P052)	C-WORTHY (P035)	C-SCAPE (P047)	All Studies
Regimen	ZEPATIER® 12 Weeks N=306	ZEPATIER® 12 Weeks N=217	EBR + GZR 12 Weeks N=101	EBR + GZR 12 Weeks N=103	EBR + GZR 12 Weeks N=(10)	N=737
Overall SVR	95% (291/306)	95% (206/217)	95% (96/101)	94% (97/103)	90% (9/10)	95% (699/737)
95% CI [¶]	(92.0, 97.2)	(91.1, 97.4)	(88.8, 98.4)	(87.7, 97.8)	(55.5, 99.8)	(93.0, 96.3)
Outcome for subjects without SVR						
On-treatment Virologic Failure [#]	<1% (1/306)	0% (0/217)	0% (0/101)	2% (2/103)	0% (0/10)	<1% (3/737)
Relapse	3% (10/306)	3% (7/217)	0% (0/101)	2% (2/103)	0% (0/10)	3% (19/737)
Other [†]	1% (4/306)	2% (4/217)	5% (5/101)	2% (2/103)	10% (1/10)	2% (16/737)
SVR by Genotype						
GT 1a	92% (144/157)	94% (136/144)	98% (52/53)	93% (67/72)	-----	94% (399/426)
GT 1b [‡]	98% (129/131)	96% (43/45)	92% (44/48)	97% (30/31)	-----	96% (246/255)
GT 4	100% (18/18)	96% (27/28)	-----	-----	90% (9/10)	96% (54/56)
SVR by Cirrhosis status						
Non-Cirrhotics [§]	94% (223/236)	94% (171/182)	95% (92/97)	93% (69/74)	90% (9/10)	94% (564/599)
Cirrhotics	97% (68/70)	100% (35/35)	100% (4/4)	97% (28/29)	-----	98% (135/138)
SVR by HIV status						
HCV mono-infected	95% (291/306)	-----	95% (96/101)	97% (71/73)	90% (9/10)	95% (467/490)
HCV/HIV-1 co-infected	-----	95% (206/217)	-----	87% (26/30)	-----	94% (232/247)
[¶] Confidence Interval based on Clopper-Pearson method. [#] Includes subjects with virologic breakthrough. [†] Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal. [‡] Includes genotype 1 subtypes other than 1a or 1b. [§] Includes 1 subject with cirrhosis status of “unknown” in C-SCAPE.						

No HIV-1 infected subjects switched their antiretroviral therapy regimen due to loss of plasma HIV-1 RNA suppression. In treatment-naïve subjects, treatment outcomes were consistent in subjects with or without compensated cirrhosis and in subjects with or without HCV/HIV-1 co-infection. Treatment outcomes were consistent in subjects with or without advanced CKD, including subjects on hemodialysis.

Clinical Trial with 8-Week Treatment in Treatment-Naïve Subjects Without Cirrhosis with Genotype 1b Chronic Hepatitis C Infection

In the C-WORTHY trial, treatment-naïve subjects with genotype 1b CHC without cirrhosis were treated with EBR + GZR with or without RBV for 8 weeks.

Demographic and baseline characteristics for treatment-naïve subjects without cirrhosis and without HIV-1 co-infection, with genotype 1b chronic hepatitis C infection treated with ZEPATIER[®] for 8 weeks are provided below.

In the C-WORTHY trial, treatment-naïve subjects with genotype 1b CHC without cirrhosis were treated with EBR + GZR with or without RBV for 8 weeks. In subjects treated with EBR + GZR without RBV, the subjects had a median age of 56 years (range: 28 to 71); 42% of the subjects were male; 81% were White; 19% were Black or African American; 3% were Hispanic or Latino; mean body mass index was 28 kg/m²; 87% had baseline HCV RNA levels greater than 800,000 IU/mL; 90% had non-C/C IL28B alleles (CT or TT); and 100% had baseline platelets $\geq 100 \times 10^3/\mu\text{L}$ and albumin ≥ 3.5 gm/dL by liver biopsy or non-invasive tests, all were non-cirrhotic and 94% (29/31) had METAVIR scores of F0-F2 and the other 2 subjects had a METAVIR score of F3.

Study Results

Treatment outcomes in treatment-naïve subjects with genotype 1b without cirrhosis who received EBR + GZR for 8 weeks in C-WORTHY are presented in Table 16. The addition of RBV was not shown to improve the treatment outcomes observed with EBR + GZR.

Table 16 – C-WORTHY: Treatment Outcomes after 8 Weeks of Treatment in Treatment-Naïve Subjects without Cirrhosis with Genotype 1b Chronic Hepatitis C Infection

Trial	C-WORTHY (P035)
Regimen	EBR + GZR 8 Weeks N=31
Overall SVR	94% (29/31)
95% CI [†]	(78.6, 99.2)
Outcome for subjects without SVR	
On-treatment Virologic Failure	0 (0/31)
Relapse	6% (2/31)
SVR by Hepatic Fibrosis Stage	
Metavir F0 to F2	97% (28/29)
Metavir F3	50% (1/2)
[†] Based on Clopper-Pearson method.	

Clinical Trials in Treatment-Experienced Subjects with Genotype 1, or 4 Chronic Hepatitis C Infection

C-EDGE TE Trial – Treatment-Experienced Subjects who Failed Prior PEG-IFN with RBV Therapy

Demographic and baseline characteristics for treatment-experienced subjects who failed prior PEG-IFN with RBV therapy with genotype 1, or 4 CHC infection are provided in Table 17.

Table 17 - C-EDGE TE: Demographic and Baseline Characteristics for Treatment-Experienced Subjects who Failed Prior Peg-IFN with RBV with or without Cirrhosis, for 12-16 weeks, with Genotype 1 or 4 Chronic Hepatitis C Infection

Trial	C-EDGE TE (P068)			
	ZEPATIER [®] 12 weeks N=105 n (%)	ZEPATIER [®] + RBV 12 weeks N=104 n (%)	ZEPATIER [®] 16 weeks N=101 n (%)	ZEPATIER [®] + RBV 16 weeks N=104 n (%)
Characteristics				
Age (Years)				
Mean (SD)	56 (10)	55 (8)	55 (10)	55 (10)
Gender				
Male	66 (63)	72 (69)	67 (66)	63 (61)
Race				
White	66 (63)	70 (67)	72 (71)	78 (75)
Black or African American	23 (22)	24 (23)	9 (9)	15 (14)
Asian	15 (14)	9 (9)	18 (18)	8 (8)
Other	1 (<1)	1 (<1)	2 (2)	3 (3)
IL28B Genotype				
CC	20 (19)	16 (15)	25 (25)	20 (19)
Non-CC	84 (80)	86 (83)	76 (75)	84 (81)
Missing	1 (<1)	2 (2)	0 (0)	0 (0)
HCV Genotype				
1a	61 (58)	60 (58)	48 (48)	58 (56)
1b	34 (32)	29 (28)	48 (48)	36 (35)
1-Other	1 (<1)	0 (0)	0 (0)	2 (2)
4	9 (9)	15 (14)	5 (5)	8 (8)
Baseline HCV RNA (IU/mL)				
> 800,000 IU/mL	84 (80)	75 (72)	83 (82)	76 (73)
Cirrhosis Status				
Non-Cirrhotic	68 (65)	69 (66)	65 (64)	68 (65)
Cirrhotic	37 (35)	35 (34)	36 (36)	36 (35)
Hepatic Fibrosis Stage(META VIR Score)[†]				
F0 to F2	49 (47)	55 (53)	53 (52)	55 (53)
F3	19 (18)	14 (13)	12 (12)	13 (12)
F4	37 (35)	35 (34)	36 (36)	36 (35)
HCV/HIV Co-Infected	6 (6)	5 (5)	6 (6)	4 (4)

[†]By liver biopsy or by non-invasive tests.

Study results

Treatment outcomes in subjects treated with ZEPATIER[®] with or without RBV for 12 or 16 weeks are presented in Table 18.

Table 18 - C-EDGE TE Trial: Treatment Outcomes after 12 or 16 weeks of Treatment in Treatment-Experienced Subjects who Failed Prior peg-IFN with RBV with or without Cirrhosis, with Genotype 1 or 4 Chronic Hepatitis C Infection

Trial	C-EDGE TE (P068)			
	ZEPATIER [®] 12 weeks N=105	ZEPATIER [®] + RBV 12 weeks N=104	ZEPATIER [®] 16 weeks N=101	ZEPATIER [®] + RBV 16 weeks N=104
Overall SVR	92% (97/105)	94% (98/104)	93% (94/101)	97% (101/104)
95% CI ^P	(85.5, 96.7)	(87.9, 97.9)	(86.2, 97.2)	(91.8, 99.4)
Outcome for subjects without SVR				
On-treatment Virologic Failure [#]	0% (0/105)	0% (0/104)	2% (2/101)	0% (0/104)
Relapse	6% (6/105)	6% (6/104)	4% (4/101)	0% (0/104)
Other [†]	2% (2/105)	0% (0/104)	1% (1/101)	3% (3/104)
SVR by Genotype				
GT 1a	90% (55/61)	93% (56/60)	94% (45/48)	95% (55/58)
GT 1b [‡]	100% (35/35)	97% (28/29)	96% (46/48)	100% (38/38)
GT 4	78% (7/9)	93% (14/15)	60% (3/5)	100% (8/8)
SVR by Cirrhosis status				
Non-Cirrhotics	94% (64/68)	97% (67/69)	92% (60/65)	96% (65/68)
Cirrhotics	89% (33/37)	89% (31/35)	94% (34/36)	100% (36/36)
SVR by Response to Prior HCV Therapy				
On-treatment Virologic Failure [¶]	89% (62/70)	91% (60/66)	92% (60/65)	95% (63/66)
Relapser	100% (35/35)	100% (38/38)	94% (34/36)	100% (38/38)
SVR by HIV status				
HCV mono-infected	92% (91/99)	94% (93/99)	94% (89/95)	97% (97/100)
HCV/HIV co-infected	100% (6/6)	100% (5/5)	83% (5/6)	100% (4/4)
^P Based on Clopper-Pearson method. [#] Includes subjects with virologic breakthrough or rebound. [†] Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal. [‡] Includes genotype 1 subtypes other than 1a or 1b. [¶] Includes null responders and partial responders				

Overall SVR was achieved in 92% and 97% of subjects receiving ZEPATIER[®] for 12 weeks and ZEPATIER[®] + RBV for 16 weeks, respectively. SVR was 100% in prior relapsers who received ZEPATIER[®] for 12 weeks, regardless of genotype or presence of cirrhosis. SVR was 100% in genotype 1b subjects who received ZEPATIER[®] for 12 weeks, regardless of the presence of cirrhosis or response to prior HCV therapy.

Among genotype 1a or 4 null or partial responders, the highest response was achieved with the administration of ZEPATIER[®] + RBV for 16 weeks. In subjects receiving ZEPATIER[®] + RBV for 16 weeks, treatment outcomes were consistent in subjects with or without cirrhosis, and no subject failed due to virologic failure. Among genotype 1a or 4, null or partial responders, SVR was achieved in 93% of subjects receiving ZEPATIER[®] + RBV for 16 weeks; 90% in subjects receiving ZEPATIER[®] alone for 16 weeks; 90% in subjects receiving ZEPATIER[®] + RBV for 12 weeks; and 84% in subjects receiving ZEPATIER[®] alone for 12 weeks.

No HIV-1 virological failures were observed in subjects who failed prior peg-IFN + RBV with HCV/HIV-1 co-infection. In treatment-experienced subjects, treatment outcomes were consistent in subjects with or without compensated cirrhosis and in subjects with or without HCV/HIV-1 co-infection.

C-SALVAGE Trial – Treatment-Experienced Subjects who Failed Prior PEG-IFN + RBV + HCV Protease Inhibitor Therapy (Boceprevir, Simeprevir, or Telaprevir)

Demographic and baseline characteristics for the C-SALVAGE trial, for subjects who failed prior peg-IFN + RBV with an HCV protease inhibitor with genotype 1 infection with or without cirrhosis treated with EBR + GZR + RBV for 12 weeks are provided in Table 19.

Table 19 – C-SALVAGE: Demographic and Baseline Characteristics for Treatment-Experienced Subjects who Failed Prior Peg-IFN + RBV + HCV Protease Inhibitor Therapy (Boceprevir, Simeprevir, or Telaprevir)

Trial	C-SALVAGE (P048)
Regimen	EBR 50 mg + GZR 100 mg + RBV 12 Weeks N=79 n (%)
Characteristics	
Age (Years)	
Mean (SD)	54 (10)
Gender	
Male	46 (58)
Race	
White	77 (97)
Black Or African American	2 (3)
IL28B Genotype	
CC	2 (3)
Non-CC	77 (97)
HCV Genotype	
1a	30 (38)
1b	49 (62)
Baseline HCV RNA (IU/mL)	
> 800,000 IU/mL	50 (63)
Cirrhosis Status	
Non-Cirrhotic	45 (57)
Cirrhotic	34 (43)
Hepatic Fibrosis Stage (METAVIR Score)[†]	
F0 to F2	37 (47)
F3	8 (10)
F4	34 (43)
Baseline NS3 resistance-associated substitutions	
Absence	43 (54)
Presence	36 (46)
[†] By liver biopsy or by non-invasive tests.	

Study results

Treatment outcome in subjects treated with ZEPATIER[®] with ribavirin for 12 weeks are presented in Table 20.

Table 20 – C-SALVAGE: Treatment Outcome in Treatment-Experienced Subjects who Failed Prior Peg-IFN + RBV + HCV Protease Inhibitor Therapy (Boceprevir, Simeprevir, or Telaprevir)

Trial	C-SALVAGE (P048)
Regimen	EBR 50 mg + GZR 100 mg + RBV 12 Weeks N=79
Overall SVR	96% (76/79)
95% CI [†]	(89.3, 99.2)
Outcome for subjects without SVR	
On-treatment Virologic Failure	0% (0)
Relapse	4% (3/79)
Other [‡]	0% (0)
SVR by Genotype	
1a	93% (28/30)
1b	98% (48/49)
SVR by Cirrhosis status	
Non-Cirrhotics	98% (44/45)
Cirrhotics	94% (32/34)
SVR by baseline NS3 resistance-associated substitutions	
Absence	100% (43/43)
Presence	92% (33/36)
[†] Based on Clopper-Pearson method.	
[‡] Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.	

Overall SVR was achieved in 96% (76/79) of subjects receiving EBR + GZR + RBV for 12 weeks. Four percent (3/79) of subjects did not achieve SVR due to relapse. Treatment outcomes were consistent in genotype 1a and genotype 1b subjects, in subjects with different response to previous HCV therapy, and in subjects with or without cirrhosis. Treatment outcomes were consistent in subjects with or without NS3 resistance-associated substitutions at baseline (see **MICROBIOLOGY**).

Based on the lack of impact of baseline NS3 resistance-associated substitutions on treatment outcomes, and efficacy analyses among treatment-experienced subjects in the C-SALVAGE and C-EDGE TE trials, the recommended treatment regimen for treatment-experienced patients who have failed peg-IFN + RBV with boceprevir, simeprevir or telaprevir is as follows: for genotype 1 relapsers, administer ZEPATIER[®] for 12 weeks; for genotype 1b prior on-treatment virologic failures, administer ZEPATIER[®] for 12 weeks; and for genotype 1a prior on-treatment virologic failures, administer ZEPATIER[®] + RBV for 16 weeks (see **DOSAGE AND ADMINISTRATION**).

Clinical Trial in Subjects with Advanced Chronic Kidney Disease with Genotype 1 Chronic Hepatitis C Infection

Demographic and baseline characteristics for the C-SURFER trial, for subjects with genotype 1 infection, with or without cirrhosis, with advanced chronic kidney disease (CKD) Stage 4 (eGFR 15-29 mL/min/1.73 m²) or Stage 5 (eGFR < 15 mL/min/1.73 m²), including subjects on hemodialysis, who were treatment-naïve or who had failed prior therapy with IFN or peg-IFN ± RBV therapy, are provided in Table 21.

Table 21 – C-SURFER: Demographic and Baseline Characteristics in Subjects with Advanced Chronic Kidney Disease who were Treatment-Naïve or had Failed Prior IFN or Peg-IFN ± RBV, with or without Cirrhosis, with Genotype 1 Chronic Hepatitis C Infection

Trial	C-SURFER (P052)
Regimen	EBR + GZR 12 weeks N=122 n (%)
Characteristics	
Age (Years)	
Mean (SD)	57 (9)
Gender	
Male	92 (75)
Race	
White	61 (50)
Black or African American	55 (45)
Asian	5 (4)
Other	1 (<1)
IL28B Genotype	
CC	32 (26)
Non-CC	88 (72)
Missing	2 (2)
HCV Genotype	
1a	63 (52)
1b	59 (48)
1-Other	0 (0)
Baseline HCV RNA (IU/mL)	
> 800,000 IU/mL	69 (57)
Cirrhosis Status	
Non-Cirrhotic	115 (94)
Cirrhotic	7 (6)
Hepatic Fibrosis Stage (METAVIR Score)[†]	
F0 to F2	87 (71)
F3	13 (11)
F4	7 (6)
No evidence of cirrhosis by biomarker	15 (12)
CKD stages	
Stage 4	22 (18)
Stage 5	100 (82)
Hemodialysis	92 (75)
Prior HCV Treatment Status	
Treatment-naïve	101 (83)
Treatment-experienced	21 (17)

[†]By liver biopsy or by non-invasive tests.

Study results

Treatment outcomes in subjects treated with ZEPATIER[®] for 12 weeks in the immediate treatment group and intensive PK arm are presented in Table 22.

Table 22 - C-SURFER Trial: Treatment Outcomes in Subjects with Advanced Chronic Kidney Disease who were Treatment-Naïve or had Failed Prior IFN or Peg-IFN ± RBV, with or without Cirrhosis, with Genotype 1 Chronic Hepatitis C Infection

Trial	C-SURFER (P052)
Regimen	EBR + GZR 12 weeks N=122 [¶]
Overall SVR	94% (115/122) [†]
95% CI [#]	(88.5, 97.7)
Outcome for subjects without SVR	
On-treatment Virologic Failure	0% (0/122)
Relapse	<1% (1/122)
Other [‡]	5% (6/122)
SVR by Genotype	
GT 1a	97% (61/63)
GT 1b [§]	92% (54/59)
SVR by Cirrhosis status	
Non-Cirrhotics	95% (109/115)
Cirrhotics	86% (6/7)
SVR by Prior HCV Treatment Status	
Treatment-naïve	95% (96/101)
Treatment-experienced	90% (19/21)
SVR by Hemodialysis Status	
No	97% (29/30)
Yes	93% (86/92)
SVR by Chronic Kidney Disease Stage	
Stage 4	100% (22/22)
Stage 5	93% (93/100)
[¶] Includes subjects in the intensive PK arm. [#] Based on Clopper-Pearson method. [†] SVR was achieved in 99% (115/116) of subjects in the pre-specified primary analysis population, which excluded subjects not receiving at least one dose of study treatment and those with missing data due to death or early study discontinuation for reasons unrelated to treatment response. [‡] Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal. [§] Includes genotype 1 subtypes other than 1a or 1b.	

Clinical Trial in Treatment-Naïve Subjects with Genotype 3 Chronic Hepatitis C Infection

Demographic and baseline characteristics in the C-SWIFT study, in treatment naïve subjects with genotype 3 CHC with or without cirrhosis, without HIV-1 co-infection, treated with ZEPATIER[®] + sofosbuvir for 8 or 12 weeks are provided in Table 23.

Table 23 - C-SWIFT Study: Demographic and Baseline Characteristics in Treatment Naïve Subjects, with or without Cirrhosis, with Genotype 3 Chronic Hepatitis C Infection

Trial Regimen	C-SWIFT (P074)	
	ZEPATIER [®] + Sofosbuvir 8 weeks N=15 n (%)	ZEPATIER [®] + Sofosbuvir 12 weeks N=26 n (%)
Characteristics		
Age (Years)		
Mean (SD)	51 (10)	48 (11)
Gender		
Male	11 (73)	18 (69)
Race		
White	15 (100)	26 (100)
IL28B Genotype		
CC	6 (40)	9 (35)
Non-CC	9 (60)	17 (65)
Baseline HCV RNA		
>800,000 IU/mL	7 (47)	14 (54)
Cirrhosis Status		
Non-Cirrhotic	15 (100)	14 (54)
Cirrhotic	0 (0)	12 (46)
Hepatic Fibrosis Stage (METAVIR Score)[†]		
F0 to F2	14 (93)	11 (42)
F3	1 (7)	3 (12)
F4	0 (0)	12 (46)

[†]By liver biopsy or by non-invasive tests.

Study results

Treatment outcomes in subjects treated with ZEPATIER[®] + sofosbuvir for 8 or 12 weeks are presented in Table 24.

Table 24 - C-SWIFT Study: Treatment Outcomes in Treatment Naïve Subjects, with or without Cirrhosis, with Genotype 3 Chronic Hepatitis C Infection

Trial	C-SWIFT (P074)	
	ZEPATIER [®] + Sofosbuvir 8 Weeks N=15	ZEPATIER [®] + Sofosbuvir 12 Weeks N=26
Overall SVR	93% (14/15)	92% (24/26)
95% CI [‡]	(68.1, 99.8)	(74.9, 99.1)
Outcome for subjects without SVR		
On-treatment Virologic Failure	0% (0/15)	0% (0/26)
Relapse	7% (1/15)	4% (1/26)
Other [†]	0% (0/15)	4% (1/26)
SVR by Cirrhosis status		
Non-Cirrhotics	93% (14/15)	100% (14/14)
Cirrhotics	-----	83% (10/12)
[‡] Based on Clopper-Pearson method.		
[†] Other includes subjects who discontinued due to adverse event, lost to follow-up, or subject withdrawal.		

Overall SVR was achieved in 92% (24/26) in treatment-naïve subjects with genotype 3 with or without cirrhosis who received ZEPATIER[®] with sofosbuvir for 12 weeks and in 93% (14/15) treatment-naïve subjects without cirrhosis who received ZEPATIER[®] with sofosbuvir for 8 weeks. Based on the overall results, including SVR in patients with cirrhosis, a 12 week regimen of EBR + GZR with sofosbuvir is recommended for treatment-naïve subjects with genotype 3 with or without cirrhosis.

MICROBIOLOGY

Mechanism of Action

ZEPATIER[®] combines two direct-acting antiviral agents with distinct mechanisms of action and non-overlapping resistance profiles to target HCV at multiple steps in the viral lifecycle.

Elbasvir is an inhibitor of HCV NS5A, which is essential for viral RNA replication and virion assembly. The mechanism of action of elbasvir has been characterized based on cell culture antiviral activity and drug resistance mapping studies.

Grazoprevir is an inhibitor of the HCV NS3/4A protease which is necessary for the proteolytic cleavage of the HCV encoded polyprotein (into mature forms of the NS3, NS4A, NS4B, NS5A, and NS5B proteins) and is essential for viral replication. In a biochemical assay, grazoprevir inhibited the proteolytic activity of the recombinant NS3/4A protease enzymes from HCV genotypes 1a, 1b, 3, and 4 with IC₅₀ values ranging from 4 to 690 pM.

Antiviral Activity

In HCV replicon assays, the EC₅₀ values of elbasvir against full-length replicons from genotypes 1a, 1b, 3a, and 4, were 0.004 nM, 0.003 nM, 0.14 nM, and 0.0003 nM, respectively. The median EC₅₀ values of elbasvir against chimeric replicons encoding NS5A sequences from clinical isolates were 0.005 nM for genotype 1a (range 0.003-0.009 nM; N=5), 0.009 nM for genotype 1b (range 0.005-0.010 nM; N=5), 0.02 nM for genotype 3a (range 0.01-0.33 nM; N=9), and 0.0007 nM for genotype 4 (range 0.0002-34 nM; N=14).

In HCV replicon assays, the EC₅₀ values of grazoprevir against full-length replicons from genotypes 1a, 1b, 3, and 4, were 0.4 nM, 0.5 nM, 35 nM, and 0.3 nM, respectively.

The median EC₅₀ values of grazoprevir against chimeric replicons encoding NS3/4A sequences from clinical isolates were 0.8 nM for genotype 1a (range 0.4-5.1 nM; N=10), 0.3 nM for genotype 1b (range 0.2-5.9 nM; N=9), 5.85 nM for genotype 3 (range 2.1-7.6 nM; N=6), and 0.2 nM for genotype 4 (range 0.11-0.33 nM; N=5).

Evaluation of elbasvir in combination with grazoprevir, ribavirin, or sofosbuvir showed no antagonistic effect in reducing HCV RNA levels in replicon cells. Evaluation of elbasvir in combination with ribavirin or sofosbuvir showed no antagonistic effect in reducing HCV RNA levels in replicon cells.

Resistance

In Cell Culture

HCV replicons with reduced susceptibility to elbasvir and grazoprevir have been selected in cell culture for genotypes 1a, 1b, 3, and 4 which resulted in the emergence of resistance-associated amino acid substitutions in NS5A or NS3, respectively. The majority of amino acid substitutions in NS5A or NS3 selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterized in genotype 1a, 1b, or 4 replicons. NS5A and NS3 amino acid substitutions were tested in either stable or transient replicon system and in some cases both systems. Maximal reduced antiviral activity is reported.

For elbasvir, in HCV genotype 1a replicons, single NS5A substitutions reduced antiviral activity: Q30D (925-fold), Q30E (56-fold), Q30H (8-fold), Q30R (125-fold), L31I (134-fold), L31M (10-fold), L31V (125-fold), H58D (6-fold), Y93C (50-fold), Y93H (600-fold), Y93N (2000-fold) by 6- to 2000-fold. In genotype 1b replicons, single NS5A substitutions reduced elbasvir antiviral activity: L31F (17-fold), L31M (7-fold), L31V (3-fold) and Y93H (17-fold) by 3- to 17-fold. In genotype 3 replicons, single NS5A substitutions reduced elbasvir antiviral activity: A30D (1280-fold), A30K (50-fold), L31F (143-fold), L31M (330-fold) and Y93H (485-fold) by 50- to 1280-fold. In genotype 4 replicons, single NS5A substitutions reduced antiviral activity: L30H (240-fold), L30F (15-fold), L30S (4-fold), P32L (5-fold), P58D (1828-fold) and Y93H (23-fold) by 4- to 1828-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of elbasvir resistance-associated substitutions further reduced elbasvir antiviral activity.

For grazoprevir, in HCV genotype 1a replicons, single NS3 substitutions reduced antiviral activity: Y56H (16-fold), A156G (5-fold), D168A (95-fold), D168E (16-fold), D168F (21-fold), D168G (32-fold), D168H (12-fold), D168I (40-fold), D168K (212-fold), D168L (11-fold),

D168N (8-fold), D168T (98-fold) D168V (56-fold) and D168Y (104-fold) by 5- to 212-fold. V36M, V55A, Q80K/L, and V107I did not impact grazoprevir antiviral activity. In genotype 1b replicons, single NS3 substitutions reduced antiviral activity: Y56H (13-fold), A156T (280-fold), A156V (375-fold), D168A (14-fold), D168F (76-fold), D168G (11-fold), D168H (51-fold), D168I (13-fold), D168K (121-fold), D168L (15-fold), D168T (26-fold), D168V (14-fold), D168Y (8-fold), R155G (28-fold), R155T (13-fold), R155W (27-fold) by 8- to 375-fold. V107I did not impact grazoprevir activity. In genotype 3 replicons, single NS3 substitutions reduced antiviral activity: N77S (7-fold), Q168R (4-fold) and Q178R (5-fold) by 4- to 7-fold. In genotype 4 replicons, single NS3 substitutions reduced antiviral activity: D168A (320-fold) and D168V (110-fold) by 110- to 320-fold. In general, in HCV genotype 1a, 1b, or 4 replicons, combinations of grazoprevir resistance-associated substitutions further reduced grazoprevir antiviral activity.

In Clinical Studies

In a pooled analysis of genotype 1, or 4 subjects treated with regimens containing ZEPATIER[®] or elbasvir + grazoprevir with or without ribavirin in Phase 2 and 3 clinical trials, resistance analyses were conducted for 50 subjects who experienced virologic failure and had sequence data available (6 with on-treatment virologic failure, 44 with post-treatment relapse).

Treatment-emergent substitutions observed in the viral populations of these subjects based on genotypes are shown in Table 25. Treatment-emergent substitutions were detected in both HCV drug targets in 23/37 (62%) genotype 1a, 1/8 (13%) genotype 1b, and 2/5 (40%) genotype 4.

Table 25 - Treatment-Emergent Amino Acid Substitutions in the Pooled Analysis of ZEPATIER[®] with and without Ribavirin Regimens in Phase 2 and Phase 3 Clinical Trials

Target	Emergent Amino Acid Substitutions	Genotype 1a N = 37 % (n)	Genotype 1b N = 8 % (n)	Genotype 4 N = 5 % (n)
NS5A	Any of the following NS5A substitutions: M/L28A/G/T/S [§] , Q30H/K/R/Y, L/M31F/M/I/V, H/P58D, Y93H/N/S	81% (30)	88% (7)	100% (5)
	M/L28A/G/T/S	19% (7)	13% (1)	60% (3)
	Q30H/K/Y	14% (5)	--	--
	Q30R	46% (17)	--	--
	L/M31M/F/I/V [†]	11% (4)	25% (2)	40% (2)
	H/P58D [‡]	5% (3)	--	20% (1)
	Y93H/N/S	14% (5)	63% (5)	20% (1)
NS3	Any of the following NS3 substitutions: V36L/M, Y56F/H, V107I, R155I/K, A156G/M/T/V, V158A, D168A/C/E/G/N/V/Y, V170I	78% (29)	25% (2)	40% (2)
	V36L/M	11% (4)	--	--
	Y56F/H	14% (5)	13% (1)	--
	V107I	3% (1)	13% (1)	--
	R155I/K	5% (2)	--	--
	A156T	27% (10)	13% (1)	20% (1)
	A156G/V/M	8% (3)	--	60% (3)
	V158A	5% (2)	--	--
	D168A	35% (13)	--	20% (1)
	D168C/E/G/N/V/Y	14% (5)	--	20% (1)
	V170I	--	--	20% (1)
[§] Reference sequences for NS5A at amino acid 28 are M (genotype 1a) and L (genotype 1b and genotype 4a and 4d). [†] Reference sequences for NS5A at amino acid 31 are L (genotype 1a and genotype 1b) and M (genotype 4a and 4d). [‡] Reference sequences for NS5A at amino acid 58 are H (genotype 1a) and P (genotype 1b and genotype 4a and 4d).				

In an analysis of genotype 3 subjects treated with ZEPATIER[®] and sofosbuvir for 12 weeks in a Phase 2 clinical study, one subject experienced relapse. This subject had a treatment-emergent NS5A Y93H substitution.

In Vitro Cross Resistance

Elbasvir is active *in vitro* against genotype 1a NS5A substitutions, M28V and Q30L, genotype 1b substitutions, L28M/V, R30Q, L31V, Y93C, and genotype 4 substitution, M31V which confer resistance to other NS5A inhibitors. In general, other NS5A substitutions conferring resistance to NS5A inhibitors may also confer resistance to elbasvir. NS5A substitutions conferring resistance to elbasvir may reduce the antiviral activity of other NS5A inhibitors. Elbasvir is fully active against substitutions conferring resistance to NS3/4A protease inhibitors: T54S, Q80K, R155K, A156T/V, D168V and D168Y.

Grazoprevir is active *in vitro* against the following genotype 1a NS3 substitutions which confer resistance to other NS3/4A protease inhibitors: V36A/L/M, Q41R, F43L, T54A/S, V55A/I, Y56F, Q80R, V107I, S122A/G/R/T, I132V, A156S, D168S, I170T/V. Grazoprevir is active *in*

in vitro against the following genotype 1b NS3 substitutions conferring resistance to other NS3/4A protease inhibitors: V36A/I/L/M, Q41L/R, F43S, T54A/C/G/S, V55A/I, Y56F, Q80L/R, V107I, S122A/G/R, R155E/K/N/Q/S, A156G/S, D168E/N/S, V170A/I/T. Some NS3 substitutions at A156 and at D168 confer reduced antiviral activity to grazoprevir as well as to other NS3/4A protease inhibitors. Grazoprevir is fully active against resistance-associated variants selected by NS5A inhibitors: L31I/M/V and Y93H.

The substitutions associated with resistance to NS5B inhibitors are susceptible to elbasvir or grazoprevir.

Persistence of Resistance-Associated Substitutions

The persistence of elbasvir and grazoprevir treatment-emergent amino acid substitutions in NS5A, and NS3, respectively, was assessed in genotype 1-infected subjects in Phase 2 and 3 trials whose virus had treatment-emergent resistance-associated substitution in the drug target, and with available data through at least 24 weeks post-treatment.

Treatment-emergent NS5A resistance-associated substitutions were generally more persistent than NS3 resistance-associated substitutions. Among genotype 1-infected subjects who had one or more treatment-emergent NS5A resistance-associated substitutions, these substitutions became undetectable at follow-up week 12 in only 5% (2/44) of subjects and 0% (0/12) of subjects with follow-up week 24 data.

Among genotype 1-infected subjects with treatment-emergent NS3 resistance-associated substitutions, these substitutions became undetectable at follow-up week 24 in 67% (10/15) of subjects based on population sequencing.

Due to the limited number of genotype 3- and 4-infected subjects with treatment-emergent NS5A and NS3 resistance-associated substitutions, trends in persistence of treatment-emergent substitutions in these genotypes could not be established.

Effect of Baseline HCV Polymorphisms on Treatment Response

Analyses in Phase 2 and 3 clinical studies of ZEPATIER[®], or elbasvir + grazoprevir, with or without ribavirin were conducted to explore the association between baseline NS5A and/or NS3 polymorphisms and treatment response among subjects who achieved SVR or experienced virologic failure (see **CLINICAL TRIALS**) and for whom baseline sequences were available. Baseline NS5A polymorphism at position 28, 30, 31, 58, and 93 were evaluated. Compared to a reference HCV genotype 1a replicon, the following NS5A substitutions reduced elbasvir antiviral activity by greater than 5-fold: M28T/A, Q30E/H/R/G/K/D, L31M/V/F, H58D, and Y93C/H/N. Baseline NS3 polymorphisms at position 36, 54, 55, 56, 80, 107, 122, 132, 155, 156, 158, 168, 170, and 175 were evaluated.

Genotype 1a

In pooled analyses of genotype 1a-infected subjects, baseline NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity *in vitro* were identified in 6% (29/491) of treatment-naïve subjects and 8% (26/334) of treatment-experienced subjects. Among treatment-naïve subjects, SVR was achieved in 98% (432/439) of subjects without baseline

NS5A polymorphisms and 55% (16/29) of subjects with baseline NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity *in vitro*. Among treatment-experienced subjects, SVR was achieved in 99% (291/295) of subjects without baseline NS5A polymorphisms and 50% (13/26) of subjects with baseline NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity *in vitro*.

In pooled analyses, presence of NS3 polymorphisms, including Q80K, prior to the start of therapy did not impact treatment response among genotype 1a-infected subjects.

Genotype 1b

In pooled analyses, presence of NS5A polymorphisms prior to the start of therapy did not impact treatment response among treatment-naïve genotype 1b-infected subjects. NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity *in vitro* were detected in 14% (36/259) of treatment-experienced subjects. SVR was achieved in 100% (223/223) of subjects without baseline NS5A polymorphisms and 86% (31/36) of subjects with baseline NS5A polymorphisms that confer greater than 5-fold reduction of elbasvir antiviral activity *in vitro*.

In pooled analyses, presence of NS3 polymorphisms prior to the start of therapy did not impact treatment response among genotype 1b-infected subjects.

Genotype 4

In pooled analyses, presence of NS5A polymorphisms prior to the start of therapy did not impact treatment response among genotype 4-infected subjects.

In pooled analyses, presence of NS3 polymorphisms prior to the start of therapy did not impact treatment response among treatment-naïve, genotype 4-infected subjects. Baseline NS3 polymorphisms were identified by population sequencing in 19% (7/36) of treatment-experienced genotype 4-infected subjects. In these subjects, SVR was achieved in 100% (7/7) of subjects with baseline NS3 polymorphisms compared with 86% (25/29) in those without baseline NS3 polymorphism.

Genotype 3

In a Phase 2 study (C-SWIFT) of ZEPATIER[®] with sofosbuvir, presence of NS5A polymorphisms prior to the start of therapy did not impact treatment response among genotype 3-infected subjects. Baseline NS5A polymorphisms were identified by population sequencing in 12% (3/25) of treatment-naïve genotype 3-infected subjects. In these subjects, SVR was achieved in 100% (3/3) of subjects with baseline NS5A polymorphisms compared with 95% (21/22) in those without baseline NS5A polymorphism.

In this analysis, presence of NS3 polymorphisms prior to the start of therapy did not impact treatment response among treatment-naïve, genotype 3-infected subjects.

No subject had NS5B polymorphisms detected at baseline.

TOXICOLOGY

General Toxicology

Elbasvir

Phospholipidosis in lymphoid organs associated with gastrointestinal tract occurred in dogs and was reversible upon treatment cessation. The No-Observed Adverse Effect Level (NOAEL) was 25 mg/kg/day (approximately 1.6 times the clinical dose based on AUC). The clinical relevance of phospholipidosis is unknown.

No target organ toxicity was identified. The NOAEL in rats, dogs, and mice was the highest dose tested, 1000 mg/kg/day (approximately 9, 7, and 63 times the clinical dose based on AUC, respectively).

Grazoprevir

The target organs identified in the repeat-dose toxicity studies were the hepatobiliary system, the male reproductive organs and the gastrointestinal tract. The safety margin for these changes was >80 times the clinical dose based on AUC.

Mutagenesis and Carcinogenesis

Elbasvir and grazoprevir were not genotoxic in a battery of *in vitro* or *in vivo* assays, including microbial mutagenesis, chromosomal aberration in Chinese Hamster Ovary cells, and in *in vivo* rat micronucleus assays.

Carcinogenicity studies with elbasvir or grazoprevir have not been conducted.

If ZEPATIER[®] is administered in a regimen containing ribavirin or sofosbuvir, the information for ribavirin or sofosbuvir on carcinogenesis and mutagenesis also applies to this combination regimen (see **product monographs for ribavirin or sofosbuvir**).

REFERENCES

- 1- Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C et al. Grazoprevir/Elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. *Journal of Hepatology* (2015), doi: <http://dx.doi.org/10.1016/j.jhep.2015.04.009>.
- 2- Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*. 2014 Nov 11. (Epub ahead of print).
- 3- Marshall WL, Yeh WW, Bethel-Brown C, Stypinski D, Auger P, Brandquist C, Gill DM et al. No evidence of pharmacokinetic drug-drug interaction in healthy subjects between

coadministered Grazoprevir (MK-5172)/Elbasvir (MK-8742) and Sofosbuvir. EASL 2015. Poster.

- 4- Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G, et al. C-EDGE coinfection: Phase 3 study of Grazoprevir/Elbasvir in patients with HCV/HIV. Poster EASL 2015.
- 5- Roth D, Nelson D, Bruchfeld A, Liapakis AM, Silva M, Monsour H Jr, Martin P et al. C-Surfer: Grazoprevir plus Elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. EASL 2015. Poster.
- 6- Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*. 2014 Nov 11. (Epub ahead of print)
- 7- Zeuzem S, Ghali R, Reddy R, Pockros PJ, Ari ZB, Zhao Y, Brown DB, et al. Grazoprevir–Elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with Chronic HCV genotype 1, 4, or 6 infection. *Ann Intern Med*. doi:10.7326/M15-0785. Published online on 24 April 2015.

**READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE
PATIENT MEDICATION INFORMATION**

 **ZEPATIER[®]**

50 mg of elbasvir and 100 mg of grazoprevir

Read this carefully before you start taking **ZEPATIER[®]** and each time you get a refill. Some of the information may have changed. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **ZEPATIER[®]**.

Remember that your doctor has prescribed this medicine only for you. Never give it to anyone else.

Your doctor might also want you to take **ZEPATIER[®]** with ribavirin or sofosbuvir. It is very important that you also read the patient product information for these other medicines if you are taking either of them with **ZEPATIER[®]**.

If you have any questions about your medicines, please ask your doctor or pharmacist.

Serious Warnings and Precautions

Hepatitis B activity (inflamed liver) may increase when taking antiviral drugs like **ZEPATIER[®]**, sometimes leading to liver failure and death. (see the “To help avoid side effects...” section, Hepatitis B Reactivation)

What is **ZEPATIER[®] used for?**

ZEPATIER[®] is used for the treatment of chronic (lasting a long time) hepatitis C virus genotypes 1, 3, and 4 infection in adults 18 years of age and older. Your treatment regimen will depend on the type of hepatitis C virus you have, whether or not you have cirrhosis (liver scarring) and your treatment history. Your doctor will decide if this drug is right for you.

How does **ZEPATIER[®] work?**

Patients with hepatitis C infection have the virus in their blood and in their liver.

ZEPATIER[®] blocks two different proteins from the virus that are needed to make new viruses, and this helps to clear the virus from the body in most people.

What are the ingredients in **ZEPATIER[®]?**

Medicinal ingredients: elbasvir and grazoprevir

Non-medicinal ingredients: colloidal silicon dioxide, copovidone, croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, sodium chloride, sodium lauryl sulfate, vitamin E polyethylene glycol succinate.

The tablets are film-coated with a coating material containing the following inactive ingredients: carnauba wax, ferrousferrous oxide, hypromellose, iron oxide red, iron oxide yellow, lactose monohydrate, titanium dioxide and triacetin.

ZEPATIER[®] comes in the following dosage form:

ZEPATIER[®] (elbasvir 50 mg and grazoprevir 100 mg)

The film-coated tablets are beige oval-shaped with the number 770 on it.

Do not use ZEPATIER[®] if:

- are allergic to elbasvir, grazoprevir or any of the other ingredients of ZEPATIER[®]. See **What are the ingredients in ZEPATIER[®]?** for a complete list of ingredients.
- have moderate or severe liver problems.
- you are taking any of the following medicines:
 - rifampin for tuberculosis
 - HIV protease inhibitors such as atazanavir, darunavir, lopinavir, saquinavir, or tipranavir
 - efavirenz (Sustiva^{*}) or etravirine (Intelence^{*}) for HIV
 - cyclosporine to stop organ transplant rejection
 - carbamazepine (Tegretol^{*}) or phenytoin (Dilantin^{*}): medicines for epilepsy and seizures
 - St. John's wort (*Hypericum perforatum*, a herbal medicine) for depression or other problems.

If you are using ZEPATIER[®] with ribavirin or sofosbuvir, read the patient information for the other products for further directions when not to use these medications.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ZEPATIER[®]. Talk about any health conditions or problems you may have, including if you:

- have ever taken any medicine for hepatitis C.
- have liver problems other than hepatitis C infection.
- have had, or are waiting for, a liver transplant.
- have any other medical conditions.
- are pregnant, or plan to become pregnant, breastfeed or plan to breastfeed.

Hepatitis B Reactivation:

Taking antiviral drugs such as ZEPATIER[®] may increase hepatitis B activity. This can lead to liver problems such as liver failure and death. Contact your doctor if:

- you have never been tested for hepatitis B
- you know you have a current hepatitis B infection
- you have had a previous hepatitis B infection

Your healthcare professional may do blood tests:

- before hepatitis C treatment
- to see the hepatitis B levels in your blood
- and may order hepatitis B treatment

Tell your doctor right away if you develop the following symptoms of liver problems such as:

- loss of appetite.
- nausea and vomiting.
- feeling tired and weak.
- abdominal pain.
- yellowing of your skin or eyes.
- colour changes in your stool.

Your doctor will decide if ZEPATIER[®] is right for you.

Other warnings you should know about:

Pregnancy and Birth Control

- Tell your doctor if you are pregnant or plan to become pregnant.
- We don't know if ZEPATIER[®] will harm your baby while you are pregnant.

ZEPATIER[®] may be used with ribavirin. Ribavirin may cause birth defects and death of the unborn baby. Extreme care must be taken to avoid becoming pregnant.

- Females must have a negative pregnancy test before starting ZEPATIER[®] and ribavirin, every month while on the medicine, and for 6 months after stopping them.
- You or your partner should not become pregnant while taking ZEPATIER[®] with ribavirin and for 6 months after you have stopped taking them.
- You and your partner must use 2 kinds of birth control while taking ZEPATIER[®] and ribavirin and for 6 months after you have stopped taking them.
- Talk to your doctor about the kind of birth control that you can use.
- If you or your partner becomes pregnant while taking ZEPATIER[®] and ribavirin or within 6 months after you stop taking them, tell your doctor right away.

Breast-feeding

- Tell your doctor if you are breastfeeding or planning to breastfeed.
- We don't know if ZEPATIER[®] gets in your breast milk and gets passed to your baby.
- It is recommended that you do not breastfeed while taking ZEPATIER[®].
- Read the ribavirin package leaflet for important breastfeeding information.

Tell your healthcare professional about all the medicines you take, including any prescription and non-prescription drugs, vitamins, minerals, natural and herbal supplements or alternative medicines.

ZEPATIER[®] and other medicines may affect each other.

The following medicines may interact with ZEPATIER[®]:

Do not take ZEPATIER[®] and tell your doctor if you are taking any of the following medicines:

- bosentan (Tracleer*): for pulmonary arterial hypertension
- modafinil (Alertec*): to help people who cannot stay awake

Tell your doctor or pharmacist if you are taking any of the following medicines:

- oral ketoconazole: to treat fungal infections
- tacrolimus: to stop organ transplant rejection
- elvitegravir, cobicistat, emtricitabine and tenofovir: a drug combination to treat HIV
- sunitinib (to treat certain cancers)
- warfarin and other similar medicines called vitamin K antagonists

Tell your doctor or pharmacist if you take any of the following medicines for lowering blood cholesterol:

- atorvastatin (Lipitor*)
- fluvastatin (Lescol*)
- lovastatin
- rosuvastatin (Crestor*)
- simvastatin (ZOCOR[®])

Also see **“Do not use ZEPATIER[®] if”**.

Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.

If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking ZEPATIER[®].

How to take ZEPATIER[®]:

Take ZEPATIER[®] exactly as your doctor tells you to take it.

- ZEPATIER[®] comes in a blister pack of individually-packaged pills. Be sure to keep the pills in this pack until you are ready to take your medicine.
- You can take ZEPATIER[®] with or without food.
- Do not stop taking ZEPATIER[®] without first talking with your doctor.

Usual adult dose:

Take one tablet a day at the same time every day. Your doctor will tell you for how many weeks you should take ZEPATIER[®].

Overdose:

If you think you have taken too much of ZEPATIER[®], contact your healthcare professional or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

It is important not to miss a dose of this medicine. If you do miss a dose, work out how long it is since you should have taken ZEPATIER[®]:

- If it has been less than 16 hours since you should have taken your dose, take the missed dose as soon as possible. Then take your next dose at your usual time.
- If it has been more than 16 hours since you should have taken your dose, do not take the missed dose. Wait and take the next dose at your usual time.
- Do not take a double dose (two doses together) to make up for a forgotten dose.

What are possible side effects from using ZEPATIER[®]?

These are not all the possible side effects you may feel when taking ZEPATIER[®]. If you experience any side effects not listed here, contact your healthcare professional. Please also see **Other warnings you should know about.**

Very common side effects of ZEPATIER[®] (more than 10%):

- headache.
- feeling tired.

Common side effects of ZEPATIER[®] (1-10%):

- abdominal pain.
- constipation.
- diarrhea.
- dry mouth.
- vomiting.
- nausea.
- weakness.
- decreased appetite.
- joint pain.
- muscle pain.
- dizziness.
- anxiety.
- depression.
- difficulty sleeping.
- irritability.
- hair loss.
- itching.

Common and very common side effects of ZEPATIER[®] when used with ribavirin:

- headache.
- feeling tired or weak.
- nausea or vomiting.
- itching.
- muscle aches.
- rash.
- trouble sleeping.
- low red blood cell counts.
- shortness of breath.
- indigestion.
- feeling less hungry.
- cough.
- feeling irritable.

Common side effects of ZEPATIER[®] when used with sofosbuvir:

- headache.
- nausea.
- diarrhea.
- feeling tired.

Your doctor will do blood tests to check how your liver is working before and while you are taking ZEPATIER[®].

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough

to interfere with your daily activities, talk to your healthcare professional.

Reporting Side Effects

You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at [MedEffect](#);
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
 - Fax to 1-866-678-6789 (toll-free), or
 - Mail to: Canada Vigilance Program
Health Canada, Postal Locator 1908C
Ottawa, ON
K1A 0K9

Postage paid labels and the Consumer Side Effect Reporting Form are available at [MedEffect](#).

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Keep ZEPATIER[®] in its original blister pack until you are ready to take it. Do not take the pills out of the original blister pack to store in another container such as a pill box. This is important because the pills are sensitive to moisture. The pack is designed to protect them.
- Keep ZEPATIER[®] at room temperature (15°C - 30°C). Protect from moisture.

Keep out of reach and sight of children.

If you want more information about ZEPATIER[®]:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](#) or Merck Canada website www.merck.ca or by calling Merck Canada at 1-800-567-2594.

To report an adverse event related to ZEPATIER[®], please contact 1-800-567-2594.

This leaflet was prepared by Merck Canada Inc.

Last Revised: June 28, 2017

[®] Merck Sharp & Dohme Corp. Used under license.

* All other trademarks are the property of their respective owners.

© 2016, 2017 Merck Canada Inc. All rights reserved.